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ABSTRACT
Treatment with androgens and anabolic steroids in conditions o f high bone
turnover seen in osteoporotic postmenopausal females has resulted in bone density
improvement. Research has demonstrated a link between muscle mass and bone due to
the mechanical demands placed on bone by muscular contractile force associated with
physical activity. This study examined whether treatment with a synthetic anabolic
steroid, 30 mg. o f nandrolone decanoate every two weeks, or placebo increased lean
mass, cross-sectional area o f thigh muscle and muscle torque production while
preserving bone mineral density (BMD) in 18 dieting, sedentary, obese, postmenopausal
females not on estrogen replacement therapy. Obesity has been associated with greater
BMD, however, previous work has suggested weight loss can precipitate the occurrence
o f a decline in BMD. Data that were collected included 24-hour urinary calcium and
phosphorusxreatinine ratios, serum osteocalcin, parathyroid hormone, total alkaline
phosphatase and 25(OH) D3. Additionally, BMD and content (BMC) were measured in
the lumbar spine and bilateral forearms with dual emission x-ray absorptiometry.
Subjects treated with nandrolone (n=8) demonstrated a significant treatment by time
increase in lean body mass with a concomitant decline in % body fat, non-significant
increase in muscle thigh volume, no significant change in fat mass and a non-significant
decline in lumbar BMD at six months. Isokinetic muscle testing demonstrated significant
increases in torque production and total work o f the upper extremities and to a lesser extent
the lower extremities torque. Non-significant decreases in weight and body mass index
occurred. Overall, there were no effects of treatment on bone turnover. The small changes in
% body fat, lean mass and torque did not have any effects on bone status. No changes

occurred in total fat mass, therefore decline in % BF occurred only due to increases in lean
mass. Addition of exercise training to nandrolone treatment might have enhanced the
increases in lean mass and strength, as well as fat mass loss, facilitating a greater strain-related
stimulation for bone formation. Further research on BMD of postmenopausal women
undergoing weight loss is indicated since they are at high risk for bone loss.

CHAPTER 1: INTRODUCTION
When older obese women with normal bone density diet to lose weight there is a
potential concern for loss o f lean body mass as well as bone mineral density and content
(BMD and BMC). Due to their postmenopausal state, the risk for bone loss, particularly
trabecular bone, is high as weight declines and less adrenal adrostenedione is aromatized to
estrone in adipose tissue. Both exercise and pharmacological agents have previously been
investigated for their effects on the modeling and remodeling processes of bone tissue to
determine if they can elicit a positive effect on minimizing high bone turnover
characteristically seen in the postmenopausal state. In order to clearly understand the
potential ramifications of significant weight loss by postmenopausal women on bone
structure, it is important to understand the basic mechanisms of normal bone turnover, the
coupling of resorption and formation and how these activites are controlled through
modeling and remodeling of the skeletal system.
M echanisms o f Bone Homeostasis
The mechanism whereby bone is laid down and resorbed is a dynamic process
under the control o f various endogenous and exogenous forces. Some o f the major
factors influencing this process are: feedback from the endocrine system,(1) nutritional
intake o f various electrolytes,<2'4) appropriate absorption o f these minerals from the
gastrointestinal system,(5'7) estrogen status in females,(8) body weight,(9,10) movement
creating a stress-strain relationship of bone and muscle0 0 and genetic influences.(3,I2)
All o f these factors are interdependently associated with bone remodeling in both
trabecular and cortical bone.
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Parathyroid hormone (PTH) is known to regulate calcium balance via direct
action on bone. It stimulates osteoclast numbers and activity, inhibits osteoblast function
and increases calcium renal distal tubular reabsorption from the glomerular filtrate, thus
increasing serum calcium levels.0* PTH is also responsible for inhibition o f phosphate
reabsorption in the renal proximal tubules and regulates control o f activation o f 1,25
(OH)2D3, the active form o f vitamin D, which is responsible for increasing calcium
absorption in the gut.(13) It is also known that vitamin D and vitamin D metabolite
receptors are located on the parathyroid gland, to provide feedback.<14)
Calcitonin, another calcitropic hormone, acts by directly inhibiting calcium
resorption from bone by its action on osteoclasts.(1) Specific receptors for calcitonin are
located on osteoclasts and in renal plasma membranes.<13) Calcitonin binding to
receptors on osteoclasts effectively inhibits resorptive actions such as mineral release
from bone, breakdown o f collagen and lysosomal enzyme changes.0*
Overall, the active process of bone remodeling involves the activity o f osteoblasts
(initiate bone formation) and osteoclasts (create bone resorption).0* The resulting
action which occurs from osteoblast to mineralization o f the bone is highly regulated and
a long-term process, in terms o f effects on bone mineral density (BMD) and content
(B M C )05* The constant interplay o f bone turnover between osteoblasts and osteoclasts
is normally coupled so that bone formation is favored over resorption, resulting in bone
density remaining relatively unchanged.03* There is, however, an age-related bone
turnover relationship which has been defined as demonstrating a peak lumbar bone
density up until age 30-35, with a decline thereafter06*
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R elationship between Muscle Mass and Bone M ineral Density
A recurrent issue in the literature regarding dynamics o f bone density is the
suggestion that lean body mass, in the form o f skeletal muscle, exerts a tremendous and
positive influence on bone preservation and formation. It has been observed that
paralysis and immobilization both result in muscle and bone atrophy.(17,18) Additionally,
weightlessness yields similar effects.(19) Although no precise mechanisms have been
identified as to the relationship between lean mass and skeletal bone density, Dalsky
(1989) suggests that the stress-strain relationship between bone and muscle, known as
Lanyon’s minimum effective strain-related stimulus defines that a level o f strain is
necessary to maintain the modeling action on bone and a higher level is required for
remodeling to occur/ 111 This force may serve to stimulate or mediate increases in
osteoblastic activity/ 111 Conroy, et al. also assert that skeletal muscle contraction
employs a localized force on bone, resulting in mediation o f bone turnover with
formation proportional to the load applied/ 201 Snow-Harter, et al. concluded that the
relationship between muscle and bone is based upon muscular strength, not just mass,
and is a much more complex issue than simple anatomy o f muscle insertion to bone/ 211
More specifically, it has been proposed that muscular strength accounts for 15%
to as high as 50% o f the variance in BMD/ 20’211 Muscle strength in the forms o f
isometric, isokinetic and isotonic contractions have all been correlated at varying levels
with BMD/ 221 Resistance exercise training, in particular, has been observed to account
for chronic skeletal loading, resulting in greater muscle mass and strength/ 201 Mikesky
has observed in felines that resistance exercise increased muscle mass and strength,
which was accounted for by an increase in cross-sectional area (CSA) o f the muscle
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fibers (hypertrophy) and an increase in numbers o f new fibers (hyperplasia).(23) Muscle
mass is a direct product o f muscle fiber weight as well as number o f myofibrils
(contractile tissue), in addition to a smaller portion of non-contractile tissue, according
to Gollnick, et al.(24) Changes that occur in muscle mass as a result o f chronic resistance
training are even seen with resistance training o f the elderly, resulting in strength
improvement due to hypertrophy and hyperplasia.(25)
The increase in muscle mass resulting from hypertrophy, as well as hyperplasia,
may produce a greater strain on bone because of the greater muscle weight and its
resulting higher contractile force. Doyle, et al. implicated muscle weight as an important
determinant for contractile activity affecting bone mass more than 20 years ago. His
methods were crude compared to current technology in that he excised and measured
wet muscle and vertebral ash weights from cadavers. This was an important first step to
identify a mechanism for muscle and bone interaction: the greater the muscle mass, the
greater possible contractile force of muscle acting upon the dynamics o f bone
turnover.(18) Since then, muscle mass and strength have been noted to serve as
predictors for BMD at various regional sites of the body (femoral neck, spine, wrist and
ankle).(20,21) It has also been suggested that the positive effects o f exercise on bone
turnover may be proportional to the magnitude o f the load applied, rather than the total
number o f loading cycles.(20) It is, therefore, important to consider that if the muscle
group is not stressed, such as with exercise, it may not potentiate an altered stress-strain
relationship to result in any effects on bone dynamics. Since exercise training is an
integral part o f chronic muscle fiber stimulation by neurological factors (recruitment of
specific motor units) exercise may be a necessary component o f the biomechanical
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relationship between bone and muscle.<25) Ironically, Frontera observed that although a
relationship between muscle mass, strength and BMD appears to exist and has been
documented in previous research, there has been no direct nor consistent correlation
between proximity o f the muscle stressed and regional BMD.
Study Rationale
There are a number of factors that can potentially influence bone turnover
dynamics. Estrogen deficiency is an important factor which has clearly been documented
to increase women’s risk for Type I Osteoporosis. The estrogen deficient female has
been observed in longitudinal studies to lose bone during perimenopausal years, in
addition to very rapid resorption at the rate o f 2-3% per year and higher for the first 8-10
years after menopause begins.(26) These women are also much more apt to become
sedentary, lose muscle mass and strength as they grow older.
Additionally, decreased BMD is an important issue to the premenopausal female.
This group may develop problems with high bone resorption as a result o f excessive
dieting and weight loss. Lukaski suggests it may be an important concern in dieting
females due to results from a 1993 study at a USDA Human Nutrition Research Center.
This USDA study focused on obese premenopausal women who lost an average o f 2-3%
o f their whole body bone density, following a five month very low calorie diet
regimen.(27) These women would be at even higher risk for osteoporosis once
menopause begins due to the fact that they would be entering estrogen deficiency with a
suboptimal peak BMD.
The current investigation presented in this manuscript was part o f a larger study
evaluating the treatment effects o f hypocaloric diet and anabolic steroid treatment over
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nine months on reduction in abdominal fat.(28) This research focused on musculoskeletal
effects o f the treatment regimen. Clearly, this group of subjects faced the risk of
accelerated bone loss due to their age and sex. The treatment regimen o f the core study
included a 500 kcal reduction in daily calorie intake from each subject’s resting metabolic
rate with the diet based upon the ADA exchange system and a maximum intake o f fat at
30% o f daily calories. Subjects also had a sedentary lifestyle and no estrogen
replacement therapy or calcium supplementation. Because of their postmenopausal
status, these women were at some risk for bone loss with weight reduction.
Anabolic steroids have been utilized in various groups o f subjects from the
nutritionally debilitated individual, to osteoporotic post-fracture patients, to the more
publicized abuse by athletes. This particular investigation focused on anabolic treatment
effects increasing lean mass, which has typically been observed. Previous research has
suggested anabolic steroids could be valuable in the treatment and prevention of
osteoporosis due to its effect on muscle mass and direct load on the bone.<18) Because
anabolic steroids facilitate an increase in muscle mass (presumably through hypertrophy
o f the contractile fibers resulting in a greater potential load on the skeleton) these effects
on muscle mass and bone were selected as the focus of the current investigation.
Purpose of the Study
The purpose o f this investigation was to test the hypothesis that treatment with a
synthetic anabolic steroid, nandrolone decanoate, results in increased lean mass with
increased muscle torque production and a pattern o f BMD and BMC preservation or
improvement, in dieting obese postmenopausal females with normal bone density. Drug
treatment o f the research subjects was accomplished by the administration o f either
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30 mg. o f nandrolone decanoate or a placebo of equal amount administered parenterally
every two weeks in a double-blind fashion.
Because muscle mass, strength and bone turnover status as a result o f anabolic
steroid treatment were important concerns, there were four predominant issues in this
study.
First, a significant issue was to observe whether diet and anabolic steroid
treatment would result in an increase in lean mass and loss o f fat mass. Second, it was
important to assess whether BMD could be preserved or increased. Third, assessment o f
change in maximal muscle force (torque) production was important due to the potential
changes in lean mass. Fourth, bone remodeling effects from anabolic treatment and diet
were examined to observe whether increasing lean mass, independent o f exercise, had
any effect on BMD in an estrogen deficient sample. Evaluation o f potential changes in
muscle CSA was o f particular interest due to the drug treatment since anabolic steroids
are known to exert a direct effect by increasing lean mass. It was imperative to observe
for potential changes through a number o f avenues: radiologically, with biochemical
markers o f bone turnover and endocrine responses.
Specific Aims
To test the hypothesis, specific aims were developed for the nine month
investigation, which identified biomechanical, biochemical, endocrine and radiological
endpoints.
Aim 1: To document body composition changes over the nine month study,
specifically by determining weight, lean and fat mass, % body fat (% BF), cross-sectional
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area (CSA) o f the left thigh, body mass index (BMI), arm circumference (AC) and
waist:hip ratio (WHR).
•

Body composition was evaluated to note if any anthropometric changes in lean and
fat mass occurred over time due to treatment. Specifically, it was hypothesized that
lean mass (total body and CS A o f the thigh) would increase and % BF, BM, BMI,
AC and WHR would decrease due to anabolic steroid treatment while fat mass
would decrease as a result o f diet intervention.
Aim 2: To compare treatment and placebo effects, without exercise training, with

respect to alterations in maximal muscle force production in both the upper and lower
extremities.
•

Maximal force production was selected as a dependent variable to document any
changes resulting from hypertrophy of the muscle tissue secondary to treatment with
nandrolone decanoate versus placebo. It was hypothesized that a pattern o f
increased muscle torque production would accompany an increase in lean body mass
due to nandrolone treatment while the placebo group muscle torque production
would decline.
Aim 3: To assess biochemical and endocrine patterns o f bone turnover, over nine

months, in response to treatment with nandrolone versus placebo.
•

Urinary levels o f calcium and phosphorus were selected as dependent variables
because they are indicative o f endocrine control o f bone homeostasis, as well as
reflecting dietary intake o f these minerals. PTH, 25 (OH) D3, total alkaline
phosphatase (Aik Phos) and osteocalcin levels were evaluated because o f their role in
bone remodeling, thus having been used previously as markers for bone turnover. As

noted previously, PTH and vitamin D are known as calcitropic hormones, which are
responsible for the major portion o f endocrine control (PTH-Vitamin D axis) o f bone
mineral turnover/4’ Osteocalcin (bone Gla-protein) represents osteoblastic activity at
the bone cellular level, in terms of remodeling. Aik Phos reflects turnover due to
osteoblastic activity in the bone and is also released from the liver and is proposed to
be a marker for bone formation in the serum. It was hypothesized that the following
pattern would be observed in subjects treated with nandrolone: a decrease in urinary
loss of calcium and phosphorus: creatinine, a decline in PTH, a rise in osteocalcin,
alkaline phosphatase and elevated 25 (OH) D3. Vitamin D (25 (OH) D3) may be
elevated if calcium homeostasis is improved. However, 25 (OH) D3 was primarily
measured to assess vitamin D status in all subjects.
Aim 4: To document changes in bone mineral density and content (BMD and BMC)
in both trabecular and cortical bone (spine and forearms ) as a response to treatment with
nandrolone versus placebo over nine months.
•

Selection o f these endpoints were important due to potential regional skeletal effects
on BMD and BMC o f trabecular and cortical bone from anabolic steroid treatment.
It was hypothesized that BMD and BMC o f the spine and forearms would be
preserved and possibly increased with nandrolone treatment whereas the placebo
group would demonstrate a decline.

Implications
Results from this study will improve our ability to identify systemic and
mechanistic effects on bone remodeling in response to anabolic steroid treatment.
Although anabolic steroids have been utilized previously in clinical treatment o f

osteoporosis, there is little evidence as to how they inhibit bone resorption and enhance
bone deposition. Perhaps by using the model o f the postmenopausal subject with normal
bone density, the actions o f this class o f drugs can be better understood. Data on muscle
mass and maximal muscle torque changes gleaned from this investigation could be
exceedingly useful since it is the older subject who benefits most from increases in
muscle mass and force due to improvement in gait, balance, ability to ambulate and
greater independence with activities o f daily living. Finally, those women who are not
suitable candidates for estrogen replacement therapy may be candidates for low dose
anabolic steroid treatment for preservation of both muscle and bone mass.

C H A PTER 2: REVIEW O F LITERA TU RE
This chapter reviews the current and significant recent scientific literature in the
areas o f the 1) physiology o f bone turnover processes, 2) relationship between muscle
strength and biomechanical load on the skeletal system (systemically and regionally) and
3) the process o f osteoporosis as defined by biochemical markers o f bone turnover.
Discussion o f various pharmacological interventions used in the current treatment o f
osteoporosis is reviewed. Additionally, there is discussion o f the action o f anabolic
steroids on muscle tissue and their role in bone mass improvement in osteoporosis
treatment. Lastly, discussion focuses on the present study, treatment with nandrolone
decanoate and its use in previous osteoporosis research.
Factors Associated with Bone Turnover
Prediction o f bone density in individuals is based upon a number o f
interdependent factors. Although many factors that influence bone density have been
identified (including age, sex, race, genetics, estrogen deficiency, calcium intake, vitamin
D3, PTH and osteocalcin levels, exercise, muscle force production, immobility, familial
history o f low bone density or osteoporosis, smoking, alcohol intake and administration
o f various medications), none are believed to serve as an independent predictor o f bone
density.(5‘!3) In particular, exercise has been studied extensively for its effect on lean
mass, since increasing muscle mass with resultant improvement in contractile force may
serve to directly increase forces on the bone. The enhanced biomechanical force on the
skeleton may stimulate increases in bone density.
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Exercise Training Effects
Observations have been made o f exercise training effects on bone mineral density
and bone mineral content changes, although a specific causal mechanism has yet to be
identified. Cross-sectional studies have shown an association between level o f physical
activity and bone mineral density.(29,30) Dalsky suggests that exercise training may
increase peak bone mass by as much as 10% and this effect is indirectly related to
Lanyon’s minimum effective strain-related stimulus/11,29) Weight-bearing exercise, which
creates a mechanical load on the skeleton and improves bone density, has been an
extensively discussed issue in the literature.01,18'29’31'331 Post-mortem studies by Doyle,
Brown and Lachance showed a strong correlation (r = 0.72) between psoas muscle
weight and the ash weight o f the L3 vertebrae. From these data, they concluded that
greater muscle mass, with its associated higher contractile force exhibited in physical
activity, serves to exert a greater direct force on the skeleton than smaller muscle mass
and is therefore a major determinant o f bone mass.081 Conversely, muscle disuse and
resulting atrophy, reflecting decreased muscle contractile force, may negatively affect
bone density in elderly patients/ 341 Vastus lateralis muscle biopsies from hip fracture
patients during surgical repair o f the femur revealed a significant decrease in fiber size, as
documented by use of a histological grading scale for muscle fiber atrophy. This was
particularly evident in the fast-twitch fibers/ 341 Heavy resistance exercise appears to
have more consistently resulted in muscle hypertrophy and bone mineral density increase
over non-loading isometric and aerobic exercise/ 32,35'391 Development o f muscle fiber
hyperplasia and hypertrophy as a consequence o f resistance training has been well
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documented in animals.(23,40> There are stii! many questions as to whether resistance and
aerobic training may result in regional or systemic skeletal changes in bone density.<30’41)
Exercise training effects on modulation o f neuroendocrine responses which are
involved with bone remodeling is one final issue which deserves consideration.
Although, there are numerous hormonal responses secondary to acute bouts o f
endurance exercise, few o f the hormones that respond are those which are normally
related to bone metabolism. Growth hormone (GH), for example, is known to increase
with exercise although a less dramatic rise is observed in trained subjects/42* Since there
is no chronic increase in GH observed with training, it is questionable but possible that
the altered pulsatility o f GH may in some way participate in remodeling for bone
preservation. There is also an increased turnover o f T3 and T4 during exercise, with a
reduced concentration o f T3 and free thyroxine at rest.<42) Trained subjects also elicit
slight elevations of cortisol during exercise and males exhibit depressed testosterone
levels.(42) Chronically elevated levels o f cortisol and thyroid hormone as well as
depressed testosterone in males would most likely not serve as a positive influence on
bone homeostasis and therefore a causal relationship between endurance training and
bone formation should be cautiously interpreted until further data becomes available.
In line with these thoughts, in a 1993 study with trained marathon runners using
endurance exercise after a period of a three-week training break, Klausen, et al. assessed
responses o f the calcitropic hormones PTH, 25 (OH) D3, 1,25 (OH)2 D3 and calcitonin.
He observed a significant decline in 1,25 (OH)2D3 while PTH rose significantly.
Transient significant reductions in serum calcium and calcitonin were documented with a
non-significant drop in 25 (OH) D3. Klausen concluded that a mechanism for inhibition
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o f 1-a hydroxylation of 25 (OH) D3 may occur with intensified endurance training but
did not postulate the specific mechanisms nor justify the decline in calcitonin and rise in
PTH.(43)

It appears at this time that there is no causal relationship defined between

endurance exercise and neuroendocrine responses which may modulate bone remodeling.
Additionally, resistance exercise has been studied for its effects on hormonal
responses. Most resistance training studies thus far have not demonstrated an increase in
testosterone levels in females, as well as there are conflicting results on responses o f
testosterone:cortisol ratios.(40) Elevated serum cortisol levels have been observed to
occur following heavy bouts o f resistance exercise although these levels do not remain
chronically high.(40) These results indicate potentially negative effects on bone status,
rather than positive influences due to the specific trends which have been documented.
Obviously, further research in the area o f resistance training, in terms o f both acute and
chronic exercise effects on the hormonal milieu need to be addressed before any
conclusions can be drawn regarding muscle and bone synthesis from this area o f the
literature.
Muscle Strength
Significant correlations between muscle strength and bone density have been
observed in human studies.(44) More specifically, muscle strength as measured
isotonically and isokinetically are good predictors o f localized bone density/22’ In
females trunk and left knee extensor (quadriceps) strength demonstrated a moderate
relationship to bone mass (r =0.40 and 0.49, p = 0.0001, respectively)/22’

Rutherford

and Jones have also observed a relationship between knee extensors muscle strength and
cross sectional area and femoral BMD in the elderly/45’
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Grip strength has also been found to correlate with BMC o f the forearm (r=
0.66, p < 0.001).(4(>) Less robust results were obtained by Bevier with observed
correlation between grip strength, forearm (radius and ulna) and spine (lumbar) density
in women (r = 0.37, r = 0.28, p< 0.05) and back strength with forearm and spine density
in men (r = 0.46, p < 0.01).(31) Back strength is believed to serve as a predictor o f trunk
and peripheral BMD in men.(31,47) Additionally, Popcock, et al., observed in post
menopausal women that:
biceps muscle strength was an independent predictor o f bone mineral
density in three sites o f the proximal femur (r = 0.56, 0.54 and 0.41, p< 0.001).<48)
Conversely, Sinaki, et al., observed in postmenopausal females undergoing a non-loading
exercise program for back extensor muscles, that improvement in back strength did not
inhibit vertebral resorption (p = 0.002).(39) This disparity between studies may be due to
the fact that the spine is composed mostly of trabecular bone, which is far more sensitive
to estrogen deficiency after menopause ensues. For this reason, exercise with
improvement in strength did not have a protective effect on the spine whereas areas with
higher cortical bone (forearm and femur) did show some protective benefit.
Osteoporosis
Osteoporosis is the primary cause o f bone mineral loss in post-menopausal
females.(3’n ’32,35,36’49'52) According to results from the Mediterranean Osteoporosis Study
(MEDOS), those individuals at higher risk for development o f osteoporosis and
subsequent fractures are very lean, tall females who currently smoke at least 2 packs o f
cigarettes/day and have a familial history o f osteoporosis.(53) This bone disease process
is defined as loss o f structural integrity of the bone due to excessive resorption.<32,54) The
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longitudinal trabeculae have been observed to become thinner while some o f the
transverse trabeculae are totally resorbed.(29,55) When resorption exceeds formation, the
integrity o f the bone is affected. This results in weakening o f the bone such that it
becomes brittle and able to endure far less mechanical strain.(55)
Normally in the skeletal system there exists a homeostasis in which bone is either
lost or laid down in direct response to the experience o f daily mechanical stress.(29,55)
During early adulthood there is usually a positive balance so that peak bone mass is
achieved but in later life when estrogen levels decline, a negative balance between bone
resorption and formation can occur.(31) The time period necessary for completion o f
initial remodeling through actual bone formation takes approximately 3'A months with
mineralization requiring an additional 3-4 months.<32,56'58)
A widely accepted method o f treatment for the prevention o f bone resorption in
postmenopausal women is estrogen replacement therapy.(32,59‘65) Type I involutional
osteoporosis which results in loss o f trabecular bone is secondary to postmenopausal
estrogen deficiency.(59) It is believed that trabecular bone may be more sensitive to
estrogen deficiency than cortical bone.(32,68> This may be due to the high surface to
volume ratio o f trabecular bone, which has a turnover rate eight times that o f cortical
bone.(69) Loss o f trabecular bone in the Ward’s triangle region o f the proximal femur
can result in aging-related proximal femur fractures.(68) Sites for increased incidence o f
fracture are the femur and spine with a doubling o f fracture risk for every 10% decrease
BMD.(48,59’66,67) Decline in vertebral bone density is approximately ten times greater
during the first five years after menopause onset than at any other time in a woman’s
life.<69) In particular, accelerated bone loss from the spine in 60 year old women is as

high as 46.8% due to its high content o f trabecular bone.(45,67) It is therefore not
surprising to observe that the highest incidence of fractures due to osteoporosis are
vertebral with the occurrence o f hip fractures having a rate only half as high.(54) The
major health care costs associated with osteoporosis, however, are related to hip
fractures due to the associated high morbidity resulting from immobility, which
ultimately leads to a high mortality rate.(8,48,70’71)
Biochemical Markers
Clinical documentation of excessive bone resorption with resulting osteoporosis
is often accomplished with the use o f numerous biochemical markers o f bone turnover.
These markers specifically reflect bone formation (osteoblastic activity) and resorption
(osteoclastic activity). These include serum PTH, urine hydroxyproline calcium and
phosphorus, reflecting bone resorption.(72) Those specific for bone formation are bone
specific or total alkaline phosphatase, 25(QH) D3 and osteocalcin.(72)
Serum PTH is known to have a stimulatory effect on bone calcium resorption.
Mid-molecule rather than carboxy terminal fragments o f PTH have been previously
observed to be significantly lower in postmenopausal subjects, although this has not
been a consistent finding.(73) PTH is directly responsible for action on the distal tubules
to increase renal absorption o f calcium as well as increase hydroxylation o f 25(OH) D3
to the physiologically active form 1,25 (OH)2 D3, which functions as a hormone.
Activation o f vitamin D3 (to the hormone form) increases intestinal absorption o f
calcium. High ionized calcium levels are a direct determinant o f lowered serum PTH
levels through a feedback mechanism.

Plasma bone-GLA protein (osteocalcin) is a specific vitamin K-dependent protein
which is synthesized by osteoblasts/6,65,73’ Vitamin K is a required co-factor in the
synthesis, which occurs due to an interaction utilizing glutamate carboxylase and vitamin
K epoxidase enzymes.(74) According to Gallop, Lian and Hauschka it is the carboxyl
groups o f the GLA residues, which enable this protein to exhibit calcium-binding
properties.(74) Osteocalcin has been demonstrated to bind strongly to hydroxyapatite in
the cow, swordfish vertebrae, bovine dentine and human cortical bone.(75) A positive
correlation has been observed between serum levels o f bone-GLA protein and lumbar
BMD measured by CAT scan (r = 0.65, p < 0.001).(73) Osteocalcin is believed to be a
useful indicator o f bone formation/6’ Currently accepted methods for assay are to
analyze for intact osteocalcin and the N-mid fragment by radioimmunoassay/72’
Other markers of bone turnover which have been frequently used are 24 hour
collections o f urine for calcium and phosphorus/6,76’ The fractional excretion o f calcium
and phosphorusxreatinine is a widely used measure o f renal tubular reabsorption o f
calcium and phosphorus according to Need, et a l.<76)
Pharmacological Treatment and Prevention of Osteoporosis
Numerous studies have been conducted concerning whether improvement in
bone density in osteoporotic patients occurs as a result o f pharmacological therapy.
Although subjects appear to respond well to preventive treatment, there are inconsistent
results in those with previously documented bone loss from osteoporosis/49,77'79’
Additionally, pharmacological treatment appears to provide no lasting effects. Once
therapy is discontinued bone mineral density returns to pre-treatment values/76,80,81’
Bisphosphonates, calcium, flouride, androgens, synthetic anabolic steroids, estrogen,
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progesterone, calcitonin, vitamin D3 and its metabolites have all been used in treatment
with varying results and side effects/7,49,51,76,79,82'86’
Anabolic Steroids
Supplementation with androgens and estrogens have been noted to act as:
“independent additive determinants o f peak bone density.”160’ Improvement in bone
density has been well documented with anabolic treatment, although the effects diminish
when treatment is interrupted/61’64’87'91’ The precise mechanism o f action o f anabolic
steroids to increase BMD is unknown. High affinity androgen binding sites have been
demonstrated in human and rat cell lines with osteoblastic phenotypes/92’
Androgens may influence intestinal responses o f l,25(OH)2 D 3 to improve
calcium uptake/93’ Nandrolone decanoate-treated women, with osteoporotic vertebral
fractures, showed a statistically significant increase in intestinal calcium absorption after
12 months o f therapy/94’ Increased lean mass, by induction o f protein synthesis in
skeletal muscle resulting in a positive nitrogen balance, has been clearly documented with
anabolic steroid treatment/84,95’ Increase in muscle mass and protein content in rats has
been suggested to be dose-dependent/96’ In rabbit studies, increased wet muscle weight
and CSA in limb muscles was documented after 12 weeks o f anabolic treatm ent/97’ Due
to the previous positive effects observed with muscle mass in the scientific literature,
evaluation o f potential changes in muscle CSA was of particular interest and included in
the methodology o f the present core study, as well as in this investigation. The question
o f whether a direct relationship exists between increased lean mass and BMD, without
exercise, however, remains inconclusive/29,62,98'99’ Doyle’s post-mortem study, however,
is the only evidence of direct correlation between muscle and bone mass, in terms o f
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contractile forces creating biomechanical stress on the skeleton/18) Since many factors
are believed to be interdependently associated with tightly regulated bone homeostasis
(resorption and formation), it is understandable that this process requires further
investigation.
Anabolic steroids have been studied extensively for use in the treatment o f post
menopausal osteoporosis. Stanozolol, a synthetic anabolic steroid, has been shown to
stimulate bone formation in conjunction with a decrease in urinary calcium excretion,
increased urinary cyclic AMP and increased serum skeletal Aik Phos activity/87,100*
There, however, can be a non-uniform skeletal increase in bone m ass/49,82* Additionally,
there is no information available on the quality of mechanical strength and stability o f this
bone replacement ,(82) Treatment in two studies, 24 and 26 months, respectively, with
methandrostenolone revealed increased lean mass, prevention o f further bone density
loss but without any increase in BMD in postmenopausal osteoporotic females/49,78*
Another synthetic anabolic steroid, Org OD 14, has demonstrated increased lumbar bone
density (8% increase after 24 months o f treatment) and it has been suggested to inhibit
bone resorption and stimulate osteoblastic activity/51* The question o f the precise
mechanism for change in BMD, however, remains controversial and unanswered.
N androlone Decanoate
Nandrolone decanoate (17B-hydroxyestr-4-en-3-one 17-decanoate); DecaDurabolin (Organon, Inc.,West Orange, NJ), the pharmacological treatment for this
study, has not been previously studied for its prospective role in improvement o f
biochemical markers for bone formation and resulting bone mineral apposition in
postmenopausal subjects without osteoporosis, although it has been studied in
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osteoporotic patients. Androgens are known to be involved in the determination o f peak
bone mass in both males and females. There is also strong evidence that testosterone or
a metabolite is directly responsible for bone development at puberty.(88) It has been
previously demonstrated that muscular tissues are more responsive to nandrolone
treatment than other tissues.(101) This is believed to be due to the strong binding
capability o f nandrolone to androgen receptors, which are located largely in muscular
tissue.<101) Nandrolone decanoate treatment has resulted in an increase in BMC and
BMD o f the forearm and lumbar spine as well as increased lean mass and decreased fat
mass in osteoporotic postmenopausal females.*37,62’63,76,93’94* In addition, increase in renal
tubular calcium reabsorption without activation o f skeletal Aik Phos has been
observed.<93) Others have not observed significant changes in BMD with nandrolone
treatment, although increases in lean mass and a decline in fat mass were documented.<64)
It has previously been suggested that increases in BMD from treatment may be related to
a decrease in bone resorption rather than an increase in bone mass.*63,102,103*
Parenteral administration o f nandrolone decanoate has been associated with
adverse side-effects. There have been reports of virilizing effects which include
hirsutism, hoarseness and deepening o f the voice.*63,89,I02,104,I05) Others have reported no
virilizing effects after long-term treatment.*103* A non-significant decline in serum highdensity lipoprotein cholesterol has also been noted with treatment over a two year
period.*63* Some androgens have been associated with hepatotoxicity, as observed from
abnormal liver function tests, jaundice and rare documented cases o f hepatic
carcinoma.*89,106*
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Summary
This chapter has set forth a number o f important issues regarding control o f bone
formation and resorption. It is evident that there are a number o f interdependent factors
that appear to be associated with bone turnover, some o f which have effects on
resorption, while others may affect formation. Although there is major control by the
endocrine system, in terms o f bone homeostasis, there are other mechanisms which play
some yet-to-be-defmed role.
One factor which required further clarification was lean mass effects on bone
density. Information has been presented that defined the anatomical and biomechanical
relationship between muscle mass, its contractile force during physical activity acting
upon bone and this action stimulating bone formation. Lanyon’s minimum effective
strain-related stimulus*29’ adequately encompasses the biomechanical force relationship
that exists between muscle and bone. Further, Doyle, Brown and Lachance have
previously demonstrated a strong correlation existed between regional muscle mass and
bone density.*18’ Their work served to clarify the importance o f muscle force, as a result
o f its mass and contractile strength on bone mass. Also muscle disuse and loss o f
contractile strength has been documented to be adversely correlated with bone mass.
There is no doubt that this biomechanical relationship between bone and muscle
exists, although the extent to which muscle strength predicts bone mass is unknown.
Weight-bearing exercise in the form o f resistance training, in particular, has been found
to increase strength, muscle mass and BMD. The theory is that increased muscle
contractile force may contribute to bone remodeling but the precise definition o f the
nature o f the exercise, relative contributions o f muscular force and mass changes as a
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result o f exercise need to be clarified. Dalsky has noted that exercise training may
increase peak bone mass by as high as 10% when optimal hormonal and nutritional
conditions exist.(U) It is important to remember, however, when interpreting Dalsky’s
conclusions that there are many other factors besides exercise that interdependently
contribute to remodeling, thus influencing bone mass.
Strength testing has demonstrated that isokinetic, isometric and isotonic muscle
strength have all been correlated to varying degrees with bone density. In addition,
strength training has resulted in a diversity o f responses by bone mass, dependent upon
the age, sex and type o f training o f the subjects. In particular, postmenopausal females
who improved back strength from an exercise program didn’t inhibit bone loss from the
spine.(39)
As previously emphasized, it is the postmenopausal female who faces the greatest
risk for bone resorption, without adequate replacement, to occur. Bone homeostasis is
no longer guaranteed with the onset o f menopause, unless estrogen replacement therapy
ensues.
One o f the most important aspects o f clinical evaluation for bone turnover has
been the advent o f biochemical markers. These provide significant documentation o f the
current status o f bone formation and resorption in subjects. Additionally, endocrine
markers and urinary markers for bone and collagen loss have been extremely useful in
developing a clear picture o f bone status in subjects.
A review o f various pharmacological treatments to improve bone density and
decrease risk for fracture has been presented. Few drugs are currently approved by the
Food and Drug Administration (FDA) for treatment o f osteoporosis, whereas numerous

24
ones are in the clinical trials phase. What is not clear with many o f the treatment options
is the quality of new bone that is formed as a result o f treatment. It is clear, however,
that positive effects on bone mass are only present with concurrent treatment and once
treatment is terminated, the positive effects cease. This is also the case with estrogen
replacement therapy (ERT), as well.
One drug treatment option which is not approved by the FDA for clinical use is
anabolic steroids. This class o f drugs has, however, been tested in research settings and
shown to increase BMD in osteoporotic subjects. O f particular interest is the question
that these drugs may increase vitamin D action on the gut to increase calcium
absorption.*93* Additionally, it has been discussed that anabolic steroids have been
demonstrated to increase lean mass. Whether this has direct implications in improving
BMD is o f importance.
Finally, nandrolone decanoate has been discussed in terms o f previous research
on osteoporotics. It has clearly demonstrated an improvement in BMD and BMC o f
both the forearms and lumbar spine of osteoporotic subjects. Nandrolone decanoate,
like other steroids, has demonstrated, in certain populations, changes in lean body mass
and bone similar to effects observed in exercise. This drug posed minimal risk to the
subjects being tested but due to this possibility, nandrolone was assigned at a lower dose
range than the osteoporosis treatment literature reflects. Although previous studies
using anabolic steroids have shown strong evidence o f increased lean mass, this
investigation served to focus on lean mass changes without exercise and whether
preservation o f BMD in non-osteoporotic females would occur.
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This investigation was needed to focus on the effects o f an anabolic steroid on
muscular force, lean mass, bone density and biochemical and endocrine indicators of
bone turnover. Results will assist in the understanding o f the inter-relationships o f lean
body mass, bone density and indicators o f osteoblastic and osteoclastic activity.

CHAPTER 3: MATERIALS AND METHODS
This study determined the effects of treatment with 30 mg. nandrolone decanoate
or a placebo on postmenopausal non-osteoporotic obese females on biomechanical,
biochemical and endocrine endpoints over a nine-month period. A dosage o f 30 mg. was
selected, although smaller than the dosage used in the osteoporosis literature, to
minimize the virilizing side effects which accompany anabolic treatment. All o f the
dependent variables were selected because o f their importance as markers o f bone
turnover (synthesis or resorption), bone density and mineral content and muscle strength
status.
Subjects
A group o f 20 healthy Caucasian postmenopausal females aged 37-62 were
recruited from the local and outlying communities by advertisement for the core weight
loss study. Subjects had a body mass index (BMI= kg/m2) between 28-42. All
participants were either surgically or naturally postmenopausal, which was confirmed by
Luteinizing Hormone (LH) levels (> 10 mlU/ml). Subjects were healthy, had normal
bone density, no evidence o f hyperlipidemia, no musculoskeletal limitations, not taking
ERT or calcium supplementation and were basically sedentary, as documented by a
physical activity history.(107) Volunteers were asked not to change their level o f physical
activity over the duration o f the study and were reassessed every three months (0, 3, 6,
and 9 months) with a physical activity history questionnaire, which quantitated the MET
hours/week and MET hours/over the past 3 months expended during work and leisure
time. The study protocol was approved by the Louisiana State University Committee on
the Use o f Humans and Animals and subjects gave their written consent to participate in
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the study with all o f its associated procedures. Subjects also signed a core study
informed consent which outlined the drug treatment, dosage and potential adverse
effects due to treatment with an anabolic agent.
All volunteers entering the study completed a stringent screening process which
included a physical examination, blood pressure assessment and clinical laboratory
evaluation including a complete blood count (CBC), Chemistry 24 panel, lipid profile,
fasting insulin and routine urinalysis. All lab work and physical examination results were
required to be within normal limits for subject inclusion into the study. Eighteen subjects
completed the study with the two drop-outs being from the nandrolone-treated group.
These subjects withdrew from the study for medical and personal reasons: one
developing migraine-like symptoms while the other subject terminated due to personal
reasons. In both cases, the reported adverse effects were not believed to be related to
nandrolone treatment.
Body Composition Assessment
Body composition for measurement of lean and fat mass (kilograms) was
evaluated by dual-energy x-ray absorptiometry (DEXA-Hologic QDR 2000,
Waltham,MA). Anthropometric assessment was done by use o f measurement o f
circumferences (waist, hip, and mid-upper arm) and calculation o f the waist:hip ratio.
The upper arm circumference was assessed using a tape measure on the right arm mid
way between the acromial and olecranon processes with the elbow bent at a 90 degree
angle and the palm supinated. The measurement was made with the arm relaxed and a
retractable inelastic tape measure touching the entire arm circumference but not
compressing or indenting tissue. Measurement was recorded to the nearest 0.1 cm. The
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waist circumference was measured with the subject standing erect and arms at the sides
with the natural waist (narrowest part o f the torso) exposed. Likewise, the measuring
tape was placed horizontal around the waist diameter o f the subject without compressing
any tissue and recorded to the nearest 0.1 cm. Finally, the hips were measured with the
subject standing erect with the arms at the sides and feet together. The examiner
squatted at the side o f the subject so the level o f dorsal protrusion o f the buttocks could
be noted. The measuring tape was placed around the dorsal protrusion o f the buttocks
in a horizontal fashion without causing tissue compression or indentation and the
measurement was recorded to the nearest 0.1 cm. BMI was calculated from height and
weight o f the subjects (kg/m2). Height was measured with use o f a stadiometer and
recorded twice, to the nearest 0.5 mm., and averaged. Weight was measured twice and
averaged, using a Detecto digital scale, which was calibrated quarterly using certified
weights from the U.S. Bureau o f Standards. Measurements were made at baseline and
after three, six and nine months o f treatment.
Bone Mineral Density and Content
Bone mineral density (BMD=gm/cm2) and content (BMC=gm) o f the lumbar
spine ( L 2 - L 4 ) and bilateral forearms were evaluated

b y

DEXA. Serial comparisons were

made at baseline and after six and nine months of treatment, respectively, with use o f the
compare mode and by matching total area scanned. Lumbar spine scans were all done
using an anterior-posterior view.(106’I07) Forearm (total radius and ulna) assessment was
made bilaterally to account for both dominant and non-dominant upper extremities.
Regions of interest were the ultra distal region and total forearm in an effort to account
for changes in cortical and trabecular bone in the appendicular skeleton.
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Daily, the DEXA underwent phantom spine calibration prior to use. Data from
calibrations were monitored and documented so that the coefficient o f variation (CV) o f
all scans would be within an acceptable range. The DEXA has consistently shown high
correlation o f precision, long-term reproducibility and longitudinal precision(52’66’108,n0' n3)
with the dual- and single-photon absorptiometry methods (DPA and SPA).(70’U4' 116) The
limitation o f the DEXA rests with the fact that it does not measure bone volume (cm3),
but rather area (cm2).(U7)
Isometric Hand Grip Strength
Bilateral hand grip strength was assessed with use o f a Jamar hand dynamometer
(TEC, Clifton, NJ). Maximal isometric voluntary contraction (MIVC) was measured
bilaterally in newtons o f force by having subjects grip the instrument maximally with
three repetitions. Subjects were instructed to alternate hand testing so as to provide a
period o f rest to each hand between maximal contractions. The maximum force
measured for three contractions was recorded for each hand and then averaged.
Measurements were made at baseline, and after one, three, six and nine months o f
treatment.
Isokinetic Muscle Strength Measurement
The Cybex II (Lumex, Ronkonkoma, NY) was used to measure isokinetic
strength o f bilateral elbow and knee flexors and extensors. The quadriceps (rectus
femoris, vastus lateralis, vastus medialis and vastus intermedius) were the major muscle
group utilized in testing knee extensors while the knee flexors (biceps femoris,
semitendinosus and semimembranosus) were the group emphasized for the knee flexors.
The biceps brachii and the biceps brachioradialis are the major muscles which comprise

the elbow flexors and the triceps brachii were the major focus o f the elbow extensors.
Subjects were required to complete 6 repetitions (reps) at 180 degrees/sec and 60
degrees/sec. A 10 second rest was given between each rep at 180 degrees/sec and a 30
second rest was given between each rep at the slower speed. Dynamic calibration o f the
dynamometer was performed by lowering different weights attached to the handle o f the
input shaft o f the dynamometer. This was completed daily before testing o f subjects was
initiated. Each subject was positioned before testing so that for the extremity being
tested the joint of interest was aligned with the dynamometer’s axis o f rotation. Peak
torque(118) (PkTq), mean torque (MnTq) and peak torque/body mass (PkTq/BM) for the
six reps were measured and expressed as newton-meters at baseline, three, six and nine
months o f the study. Total work (area under the torque curve) was measured at
baseline and at nine months for all muscle groups tested.
Thigh Muscle Volume
The cross-sectional area o f the left thigh muscle was measured at baseline and
every three months as part of this investigation and the core study methodology, with
use o f computerized axial tomography (CAT) scan (Siemans,DRH, NJ). Measurement of
the CSA o f the thigh 100 cm. below the ischial tuberosities was done with a set scan
thickness of 8.0 mm. The CSA (cm2) of the muscle was determined with use o f the
computer software by summing all pixels within a range of 30-80 Houndsfield units.
Laboratory Methodology
Twenty-four hour urinary calcium and phosphorus to creatinine ratios were
measured at baseline, and at one, three, six and nine months o f the study to observe any
change in bone turnover patterns.(6,65,U9) Subjects were instructed to keep a food record
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for 24 hours preceding and during the 24 hours o f collection, in order to assess calcium,
phosphorus and sodium intake. Written guidelines were also given to the subjects
regarding consuming an intake o f 800 mg o f calcium during this time period, in an effort
to provide some control on their calcium intake during urine collection.
Creatinine was measured with use o f the Beckman Synchron CX5 (Beckman
Instruments, Inc., Brea, CA) using the Jaffe method which creates a creatinine-picrate
complex and monitors for rate o f change in absorbance.
Urine was acidified by adding 5.0 ml of 6 N HC1 to the 24-hour container, prior
to collection. Analysis was done using a 1:10 dilution with use o f the Perkin Elmer
P I 000 ICP which scanned the chemically specified wavelengths to determine the peak
area o f the urine specimen, specific for calcium and phosphorus. Additionally, at
baseline and every three months, measurements o f serum osteocalcin, parathyroid
hormone (PTH), 25 (OH) D and total Aik Phos were completed. Total Aik Phos was
measured using the Beckman Synchron CX5 using an enzymatic rate method. Serum
osteocalcin and 25 hydroxyvitamin D3 were analyzed in duplicate by using a
radioimmunoassay method (RIA, INCSTAR), while PTH was assessed using a
immunoradiometric assay (IRMA) (INCSTAR, Stillwater, Minn.).<6,65) These assays
were read using a RIASTAR 20 well gamma scintillation counter (Packard Instruments,
owners Grove, II.). Blood samples were drawn after a 12-hour overnight fast between
8:00-8:30 A.M. through an indwelling intravenous catheter in the antecubital space.
Samples were drawn and immediately transferred to a glass evacuated tube. The blood
was allowed to clot and spun at 1949 rpm for 15 minutes with the serum drawn off
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immediately and aliquoted for the various tests. Samples were frozen at -60 degrees C
until analysis.
Osteocalcin analysis utilized the simultaneous addition o f the iced serum sample,
osteocalcin antibody and 125I osteocalcin, with subsequent overnight incubation for lb24 hours. Following phase separation, centrifugation, decantation and a 2 hour + 15 min
incubation at 2-8 degrees C, the tubes were read for 60 seconds.(64,72)
Vitamin D was a two-step procedure involving the rapid extraction o f 25(OH)
D3 and its hydrOxylated metabolites from the serum sample. Following this, the sample,
tracer and 25(OH)D antibody were incubated for 90 minutes at 20-25 degrees C. There
was a subsequent addition o f a precipitating complex and re-incubation. Following
centrifugation and decantation, the supernate was read. 25(OH) D3 was selected
because it is the predominant circulating form of the vitamin and is referenced as the
most reliable index o f vitamin D status.(120)
PTH utilized an assay with two polyclonal antibodies which are specific to PTH
1-34 (C-terminal region) and 39-84 (mid-region). Iced serum samples were incubated
with the N-tact PTH SP bead for 22 + 2 hours at 20-25 C. Following this, the sample
was decanted with the beads washed four times and the intact PTH bound to the SP bead
was counted. These biochemical and endocrine markers (serum osteocalcin, total Aik
Phos, PTH, 25(OH) D3 as well as urinary calcium and phosphorus/creatinine), in this
study were selected in an effort to clearly document any patterns o f change in bone
turnover as a result of anabolic steroid treatment in the subject sample.
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E xperim ental Design and Statistical Analysis
This out-patient parallel group design with repeated measures involved a nine
month period o f double-blind drug or placebo treatment, depending upon randomized
group assignment o f 20 subjects. Eighteen subjects completed the study. It was part of
a larger study assessing the energy expenditure, insulin action and abdominal and total
body fat loss secondary to treatment with nandrolone decanoate, placebo or aldactone
with hypocaloric diet in 30 moderately obese post-menopausal females.
The dependent variables in this study were examined utilizing an analysis o f
variance (ANOVA) with repeated measures where there was a 1 between-subjects factor
(nandrolone drug treatment) and 1 within-subjects factor (time). In situations where the
data violated the ANOVA assumption o f sphericitity the corresponding p-values were
corrected using the Hunyh-Feldt adjustment. Post-ANOVA analysis involved a series of
1 degree o f freedom contrasts (selected a prioi) or simple ANOVAs depending on the
effect being probed. Post-ANOVA tests were driven by the appropriate F-test and the
experimentwise error rate (0.05) was maintained throughout all post-ANOVA tests. The
time periods selected for re-evaluation o f the bone density (baseline, 6 and 9 months)
were chosen because they were believed to be o f a sufficient period to note changes
because o f normal bone metabolic mechanisms.(35,40,41’44’79)

CHAPTER 4: RESULTS
Summary tables for treatment by time interactions and post hoc analysis results
are listed below (Tables 1 and 2.). Subject characteristics at baseline and additional time
by treatment interactions are found in Appendix B.
Table 1. Sum m ary of Treatm ent by Time Interactions
D ependent Variable
LBM
% BF
Lumbar BMD
Left MI VC
Right Elbow Flexors PkTq at 180 dps
Right Elbow Flexors MnTq at 180 dps
Right Elbow Flexors PkTq/BM at 180 dps
Left Elbow Flexors PkTq at 180 dps
Left Elbow Flexors MnTq at 180 dps
Left Elbow Flexors PkTq/BM at 180 dps
Right Elbow Flexors MnTq at 60 dps
Left Elbow Flexors PkTq at 60 dps
Left Elbow Flexors MnTq at 60 dps
Left Elbow Flexors PkTq/BM at 60 dps
Right Elbow Extensors PkTq at 180 dps
Right Elbow Flexors PkTq/BM at 180 dps
Left Elbow Extensors PkTq at 180 dps
Left Elbow Extensors PkTq/BM at 180 dps
Right Knee Extensors PkTq at 180 dps
Right Knee Extensors MnTq at 180 dps
Right Knee Extensors PkTq/BM at 180 dps
Right Knee Extensors PkTq at 60 dps
Right Knee Extensors MnTq at 60 dps
Right Knee Extensors PkTq/BM at 60 dps
Right Knee Flexors MnTq at 60 dps
Right Elbow Flexors Total Work at 180 dps
Right Elbow Flexors Total Work at 60 dps
Left Elbow Flexors Total Work at 60 dps
Right Elbow Extensors Total Work at 60 dps
CSA Thigh
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Value
0.0001
0.01
0.02
0.03
0.0003
0.0009
0.002
0.013
0.02
0.03
0.04
0.004
0.02
0.03
0.005
0.014
0.03
0.05
0.002
0.008
0.009
0.0003
0.002
0.004
0.03
0.02
0.0004
0.0002
0.014
0.0003
d
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Table 2. Post Hoc Analysis for T reatm ent by Time Interactions
N
PL
a
D ependent V ariable
0.025
NSD
BL,3M<6,9M
LBM
BL>3M
BL>3,6,9M
0.025
% BF
NSD
0.025
NSD
Lumbar BMD
NSD
0.025
NSD
Left MIVC
0.025
NSD
BL<6,9M
Right Elbow Flexors PkTq at 180 dps
0.025
BL<6,9M
NSD
Right Elbow Flexors MnTq at 180 dps
BL<6,9M
NSD
Right Elbow Flexors PkTq/BM at 180 dps 0.025
NSD
0.025
NSD
Left Elbow Flexors PkTq at 180 dps
NSD
0.025
NSD
Left Elbow Flexors MnTq at 180 dps
NSD
NSD
Left Elbow Flexors PkTq/BM at 180 dps 0.025
0.025
BL<6,9M
NSD
Right Elbow Flexors MnTq at 60 dps
BL<6,9M
0.025
NSD
Left Elbow Flexors PkTq at 60 dps
BL<6,9M
0.025
NSD
Left Elbow Flexors MnTq at 60 dps
BL<6,9M
0.025
BL<3M
Left Elbow Flexors PkTq/BM at 60 dps
BL<9M
NSD
Right Elbow Extensors PkTq at 180 dps 0.025
NSD
BL<9M
Right Elbow Flexors PkTq/BM at 180 dps 0.025
0.025
BL<9M
Left Elbow Extensors PkTq at 180 dps
NSD
BL<6,9M
Left Elbow Extensors PkTq/BM 180 dps 0,025
NSD
0.025
NSD
6M>BL,3,9M
Right Knee Extensors PkTq at 180 dps
0.025
NSD
6M>BL,3,9M
Right Knee Extensors MnTq at 180 dps
0.025
Right Knee Extensors PkTq/BM 180 dps
NSD
6M>BL,3,9M
0.025
Right Knee Extensors PkTq at 60 dps
BL>3,6,9M NSD
0.025
Right Knee Extensors MnTq at 60 dps
BL>6,9M NSD
0.025
BL>9M
NSD
Right Knee Extensors PkTq/BM 60 dps
0,025
9M<3,6M NSD
Right Knee Flexors MnTq at 60 dps
Right Elbow Flexors Total Work 180 dps 0.025
NSD
9M>BL
Right Elbow Flexors Total Work 60 dps 0.025
9M>BL
NSD
0.025
Left Elbow Flexors Total Work 60 dps
NSD
9M>BL
Right Elbow Extensors Total Work 60 dps 0.025
NSD
NSD
0.025
BL>6,9M NSD
CSA Thigh

Body Composition
A significant treatment by time interaction was observed for lean body mass and
% body fat. The nandrolone (N) treated group demonstrated a higher lean body mass
(LBM) at six months (6M) and nine months (9M) versus at baseline and three months
(3M). To the contrary, there were no significant improvements in LBM in the PL group
throughout the study period, rather non-significant losses. Additionally, percent body fat
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(% BF) at 3M, 6M and 9M were significantly reduced versus baseline in the N group.
The N group started at baseline with a higher (but not significantly) % BF than placebo
(PL) and continued to lose until 6M where it plateaued. The PL group significantly
reduced their % BF at 3M versus baseline but made no additional reductions at 6M and
9M. Initial changes in body fat presumably occurred due to the hypocaloric diet regimen
the subjects were assigned to follow throughout the study.
Significant main effects for time were detected for body mass (BM) (p = 0.001),
body mass index (BMI) (p = 0.0001), arm circumference (AC) (p = 0.0032) and fat mass
(FM) (p = 0.0001) because the baseline values for both groups were greater than any
other time point in the study. There were no significant changes observed in the
waist:hip ratio (WHR) over the course of the study.
In summary, the nandrolone treated subjects increased lean body mass and
decreased their % body fat over time to a greater extent than the placebo group,
however, did not lose fat mass significantly different than placebo-treated subjects.
There were no group differences in weight, fat mass, or regional fat distribution as
expressed by waist:hip ratio and arm circumference. It is important to emphasize that
the resulting significant decline in % body fat in the nandrolone treated subjects occurred
due to the increase in lean mass alone.
Bone Mineral Density and Content
There was a significant treatment by time interaction (p = 0.02) for bone mineral
density (BMD) in the lumbar spine. Post hoc analysis did not detect significant
differences over time for either group but the significant interaction may be due to a
slight decline in the BMD at 6M for the N group only. Following this decline, BMD
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values returned to near baseline at 9M. Otherwise, no significant difference was
observed between the groups for BMD and bone mineral content (BMC) o f the lumbar
spine.
With respect to the bilateral total forearm (radius and ulna) bone density, the PL
group demonstrated a significantly higher BMC than the N group at baseline and
throughout the study (left forearm: F = 7.194, p = 0.0164; right forearm: F = 6.171, p =
0.0244). A significant main effect for time, across both groups, was observed for both
BMD o f bilateral total forearms and for BMC of the right forearm. This effect was
explained by the baseline BMD being significantly greater than the 6M and 9M values for
the right total forearm, while BMD was greatest at baseline versus 6M in the left
forearm. Additionally, the baseline BMD and BMC were greater than 6M values for the
left total forearm. There were no detectable differences across time with use o f post hoc
analysis for the right total forearm BMC.
A significant main effect o f time was observed for BMD o f the right ultra-distal
(UD) forearm (p = 0.032) and BMC of the left UD forearm region (p = 0.002). These
effects were accounted for by the larger baseline BMC and BMD values versus 6M.
In summary, nandrolone treatment did not serve to protect or preserve the
subjects BMD and BMC over PL. In the case o f the total forearm and UD forearm,
there was loss o f BMD and BMC which occurred in both N and PL groups, signifying
there were no treatment effects.
Isometric Hand Grip Strength (MIVC)
A significant treatment by time interaction was noted only for the left maximal
isometric voluntary contraction (MIVC) but not the right. Post hoc testing did not
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detect differences over time for either group, with respect to the left MIVC. The
interaction was probably caused by the N group grip strength being lower than PL at
baseline but higher at 9M.
Isokinetic Muscle Strength Measurement
A significant treatment by time interaction was observed for peak torque (PkTq),
mean torque (MnTq) and peak torque per body mass (PkTq/BM) for bilateral elbow
flexors at 180 degrees/second (dps). The right elbow flexors torque at 180 dps
demonstrated a significant increase from baseline to 6M and 9M for all three dependent
variables for N, as was identified by post hoc analysis. The post hoc analysis, however,
did not reveal specific differences over time for PL or N-treated groups with respect to
the left elbow flexors. The interaction for the left elbow flexors data was due to a
marked increase in the N-group from baseline to 3M and with a continued increase from
6M to 9M, whereas the PL group did not change significantly over time. Additionally, at
60 dps there was a significant treatment by time interaction for MnTq o f the right elbow
flexors caused by the N-treated group with the 6M and 9M torque being greater than
baseline. The left elbow flexors showed significant treatment by time interaction for all
three dependent variables, with PL demonstrating no significant change over time from
the post hoc analysis with N eliciting an increase in torque at 6M and 9M versus
baseline.
With regard to the right and left elbow extensors, there was a significant
treatment by time interaction for PkTq and PkTq/BM at 180 dps, while the right elbow
extensors also showed a time effect for MnTq. The interaction was related to the
significantly lower baseline PkTq and PkTq/BM versus at 6M and 9M for the left elbow
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extensors for N while the right elbow extensors torque was significantly lower at baseline
versus the PkTq at 9M. The right elbow extensors at 60 dps demonstrated only a time
effect for PkTq/BM, for which baseline torque was significantly less than at 6M.
There was a significant treatment by time interaction for PkTq, MnTq and
PkTq/BM for the right knee extensors at 180 dps. The post hoc analysis revealed that
the N group PkTq, MnTq and PkTq/BM were significantly greater at 6M than at any
other time point. There was also a significant treatment by time interaction for PkTq,
MnTq and PkTq/BM of the right knee extensors at 60 dps. Post hoc analysis noted a
larger torque at baseline than other time points for PL. Finally, the left knee extensors
were noted to exhibit a significant effect for time only for PkTq/BM at 180 dps with a
peak observed at 6M.
Time by treatment effects for the right knee flexor MnTq at 60 dps were detected
and with post hoc analysis it was determined that the differences occurred in the PL
group, with a decline in torque over time (9M < 3M and 6M). To the contrary, no
differences were detected in the N-treated group.
A significant effect for time was demonstrated for bilateral knee flexors PkTq,
MnTq and PkTq/BM at 180 dps and at 60 dps for the right knee flexors for PkTq, MnTq
and PkTq/BM. These all revealed that the difference existed at 6M, which was the peak
response for all the knee flexors values showing significance.
Total work (area under the torque curve) was measured pre- and post study for
all muscle groups tested at both 180 and 60 dps. A significant treatment by time
interaction (p = 0 .02) was observed for bilateral elbow flexors at 60 dps and the right
elbow flexors at 180 dps. Post hoc analysis demonstrated N to show a significant work
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increase for the right elbow flexors at 9M versus baseline (p = 0.025) at both speeds and
the left elbow flexors at 60 dps. Conversely, PL did not change their total work over
time.
A treatment by time interaction was also documented for total work o f the right
elbow extensors at 60 dps, however no specific differences could be determined by post
hoc analysis. This was probably caused by a pattern o f increase in total work from
baseline to 9M in N. Significant time effects were also observed for the left elbow
extensors at both speeds, with total work greater at 9M over baseline.
Regarding the lower extremities, significant time effects for both N and PL
treated groups were only seen for bilateral knee extensors at 60 dps with baseline work
being greater than at 9M. No time effects were seen for bilateral knee flexors.
In summary, significant differences with respect to the N treated group were
observed particularly in the upper extremities over time. Both the left and right elbow
flexors torque increased over time when tested at 180 dps for N but not PL, whereas
elbow extensors changes were only based upon time effects. In the lower extremities,
the PL group demonstrated a decline in torque over time with respect to the right knee
extensors and knee flexors at 180 and 60 dps. N only revealed a peak at 6M for the right
knee extensors torque (peak, mean and per body mass). Total work increases were seen
to a greater extent in the upper extremities. The N group documented significant
increases for the elbow flexors and the right elbow extensors between pre- and post
study. Bilateral knee extensors at 60 dps only showed time effects for both groups.
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Thigh Muscle Volume
A significant treatment by time interaction was noted for cross-sectional area
(CSA) o f the thigh. Post hoc analysis revealed that the baseline volume was greater than
at 6M and 9M for PL. Conversely, the N-treated group demonstrated a non-significant
increase in thigh muscle CSA over time.
Endocrine Markers
There were no significant main effects observed for parathyroid hormone (PTH),
whereas 25 (OH) D3 demonstrated a main effect for time for both groups. This was
accounted for because vitamin D values for both groups were significantly greater at
baseline than at any other time point in the study. The mean coefficients o f variation (%
CV) for these assays were 10.51 and 6.11%, for vitamin D and PTH, respectively. The
normal ranges in this investigation for vitamin D and PTH were 10.00-50.00 ng/ml and
13.00-54.00 pg/L, respectively.
Biochemical Markers
There was a significant main effect for time in the urinary calciumxreatinine ratio
with no specific differences detected between time points. Conversely, the phosphorus:
creatinine ratio was significantly greater at baseline than at 3M, 6M or 9M. There were
no significant differences between the PL and N- treated groups for alkaline phosphatase
(Aik Phos), osteocalcin (OC), and urinary calciumxreatinine and phosphorusxreatinine
ratios. The mean CV for osteocalcin was 5.14% with a normal range o f 1.80-6.60
ng/ml. The mean interassay coefficients of variation for urine calcium and phosphorus
were 0.682% and 2.4%, respectively.

Diet records were kept by the subjects 24 hours preceding and the 24 hours
during urine collection at baseline, 1M, 3M, 6M and 9M. Subjects received specific
written and verbal instructions regarding the required information and amounts to be
documented. Additionally, subjects were instructed to consume 800 mg. o f calcium in
their daily intake o f food, to provide consistency o f intake. Review o f the records and
analysis by a nutritional database revealed records were poorly kept by subjects. A
significant correlation between phosphorus and sodium intake and urinary phosphorus
excretion was observed at 3M for N. Correlations were r = 0.87, p = 0.001 for
phosphorus intake and excretion while r = 0.69, p = 0.010 for sodium intake and
phosphorus urinary loss. No other time points were found to have significant correlation
for dietary intake and urinary loss of these electrolytes.

CHAPTER 5: DISCUSSION
This investigation assessed prevention of loss o f bone density, with respect to a nine
month weight loss program, in obese postmenopausal females with normal bone density.
Weight loss was modest in view o f the amount o f weight that could have been lost over
the course of the study. The discussion focuses on treatment effects from nandrolone in
this case o f minimal weight loss. Numerous treatment by time effects will be discussed
which revealed a difference in the pattern o f change across time between the placebo and
nandrolone-treated groups.
The observation o f treatment by time effects on lean body mass is compatible with
results from other investigations that have demonstrated increased lean mass with
anabolic steroid treatment. The CSA changes o f the thigh were consistent with overall
LBM increases. The nandrolone-treated group demonstrated a non-significant increase
in muscle mass while PL declined (baseline > 6M, 9M). There was a strong trend for a
treatment main effect, which reflected muscle mass preservation with nandrolone
treatment (F = 4.483, p = 0.0514). Conversely, the placebo group demonstrated a non
significant decline in thigh CSA over nine months.
There was also an expected decline in % BF in both groups which was probably due to
the hypocaloric diet utilized in the core study. The N group demonstrated a decline in %
BF until 6M, when a plateau occurred, although 3M, 6M and 9M were all significantly
reduced from baseline. The PL group also had a significant decline in % BF at 3M and
6M versus baseline. Subjects appeared to have a loss o f interest for participation in the
calorie restricted phase o f the study before 6M, as reflected by the limited amount of
weight loss. Unfortunately lack o f diet compliance resulted in minimal weight loss which
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was not near the anticipated goal. The expected weight loss was that subjects BM
would decline by at least 13.64 kg (30 lb.) during the course o f the study so that weight
loss effects on the postmenopausal skeletal system could be observed. Subjects from the
N group went from a weight of 87.4 + 8.2 kg at baseline to 84.9 ± 8.7 kg at 9M (a loss
o f 2.5 kg). The PL group began with a mean weight of 86.7 + 7.5 and completed the
study at 81.7 + 8.1 kg (a loss o f 5 kg). These small changes in body weight were
reflected in a minimal decline in % BF and a non-significant decline in LBM until 6M
when it plateaued in the PL group. N did demonstrate significant improvement in LBM
and decrease in % BF. This pattern o f change in lean body mass with nandrolone
treatment was presumably due to the high binding affinity o f this anabolic agent to
androgen binding receptors in skeletal muscle because o f the low a-reductase activity in
skeletal muscle as reported previously.
There must, however, be a cautious interpretation o f the significant decline in %
body fat from nandrolone treatment. There were no significant differences between
groups with regard to loss of body fat which means that the decrease in % BF was
strictly due to the increase in lean mass alone, not to total fat mass losses. Additionally,
the plateau in the decline in % BF at 6M was concurrent with the plateau in the change
in LBM for both groups. The hypothesis was partially supported because LBM
increased significantly and a trend was observed for increased thigh CSA. Since weight
loss was modest, other body composition changes related to fat mass losses were not
seen (BMI, FM, BM, AC and WHR).
The treatment by time interaction for lumbar bone density was an important
observation with technical relevance. Evaluating the data one sees that the spine BMD
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decreased non-significantly at 6M in the N group and returned to near baseline levels at
9M. The length o f time required for osteoblast action and mineralization to occur is a
minimum o f 6-9 months, therefore other possible anatomical factors or a chance
variation in measurement procedures presumably affected the scan resolution. In terms
o f method, all scans were analyzed in the compare mode and the total area scanned (cm2)
was matched to the baseline scan. The core study, which assessed subcutaneous and
visceral abdominal fat changes in the subjects provided the best explanation to this
phenomenon of decline in BMD at 6M, with return to near baseline levels at 9M. The
visceral fat in the N group increased significantly from 153 cm2 at baseline to 161 cm2 at
6M.(28) The BMD finding is consistent with this investigator’s previous observation that
abdominal thickness is correlated with a decline in resolution o f the DEXA BMD scan in
the lumbar region.(121) This was previously observed using data from lateral thickness
measurements and lateral lumbar BMD lumbar scans in this group o f subjects (r =
0.516, p < 0.05) and confirmed as a methodological problem by the company that
manufactures the DEXA. However, they stand by the quality o f A-P lumbar scans as
being unaffected by abdominal thickness, except in the case o f the morbidly obese.
Additionally, a significant decline in BMD o f bilateral total forearm (radius and
ulna) was observed over time for both groups as reflected by higher baseline versus 6M
and 9M for BMD o f the right forearm and baseline > 6M for the left forearm. A strong
trend towards significance (p = 0.054) was observed for BMC decline over time for the
left forearm, while a significant effect for time was noted for BMC o f the right forearm.
A trend (p = 0.07) was also noted for a main effect o f time for BMD o f the left forearmUD. The overall effect noted was that both groups lost some forearm BMD and BMC
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throughout the investigation, although their results were still well within normal limits
for the mean for their age and sex.
In the case o f bone density preservation with anabolic treatment, the hypothesis
was not supported by these data. The increase in LBM observed in the N group
appeared to have no effect on preservation o f cortical bone in the appendicular skeleton,
as well as trabecular bone in the spine and ultra distal region o f the forearms. Aside from
the methodological discrepancies o f the DEXA, the results demonstrate that nandrolone
treatment did not serve as a protective measure for maintaining BMD at least during a 9
month period. Even with significant increases in LBM and PkTq, MnTq and PkTq/BM
in isokinetic work, there was no increase nor preservation o f baseline BMD and BMC.
These results are inconsistent with those o f Popcock, et al, who observed muscle
strength to serve as a strong predictor for BMD in the femur and forearm.(48) Popcock
studied healthy women who did not vigorously exercise, with an average age o f 45 years.
He concluded that bone loss in the proximal femur may be modulated by muscle
strength, body mass and physical fitness o f the subject.(48) These, o f course are issues
related to chronic mechanical loading to facilitate remodeling. Although the small
increases in LBM from the current investigation, did not result in any positive effects on
BMD, it would be interesting to observe whether larger increases in LBM as a result o f
drug treatment and exercise could modulate BMD.
One important consideration to the process o f bone remodeling is exercise. The
subjects in this study were prohibited from increasing their exercise regimen. It is
plausible that the muscle biomechanical effects on the skeletal system might have been
greater if subjects had been allowed to physically train, in conjunction with the drug

treatment regimen. Increased physical training was, however, viewed as a possible
confounding factor and therefore carefully controlled in the subjects through the course
o f the study. It is also important to note that since the expected weight loss did not
occur, there was less of a real test to skeletal system remodeling in an estrogen deficient
sample population. Additionally, the nandrolone dosage utilized in this investigation was
lower than reported in the literature as having positive effects on BMD in osteoporotics.
It is conceivable that this may have been a suboptimal dosage, which would not elicit the
expected effects on the skeletal system. However, serious consideration would have to
be given before increasing the dosage since even at this treatment level some subjects
demonstrated virilizing effects.
Another consideration which must be addressed is that these subjects began the
study with normal BMD and BMC in the lumbar spine and forearm regions, even though
they were estrogen deficient. Nandrolone decanoate has been used in clinical trials for
treatment o f osteoporotics in which subjects initiated treatment with BMD significantly
below the mean for their age and sex. Therefore, even small changes in BMD in
reported samples would be significant. Conversely, the sample in the present
investigation began with an above average BMD presumably due to their obesity. In this
population, changes in LBM and strength did not effect any change in BMD.
Additionally, if exercise had been a concurrent part o f the treatment regimen with
nandrolone it is not known whether a resulting increase or preservation o f BMD would
have been observed. It is also not known what effects this treatment regimen would
have demonstrated in subjects with an initial low BMD.

The association between higher BMD and obesity has previously been attributed
in the literature to several possible mechanisms. First, it has been suggested that in
overweight subjects aromatization of androstenedione to estrone occurs in subcutaneous
adipocytes, which may serve to keep the subject in an estrogen sufficient state.(120,121)
Although adrostenedione and testosterone both decrease with the onset o f menopause
(1800 to 750 pg/ml and 300 to 250 pg/ml, respectively) total estrogen production may
actually be greater in the obese over the slender subject.(123’124) This effect is presumably
even more predominant with obese postmenopausal subject since extraglandular
formation of estrone from androstenedione is the primary route o f conversion for this
hormone.(124) Additionally, increased LBM to support the greater fat mass in the obese
may also serve as a larger biomechanical force on the skeleton, which could have
resulting effects on facilitating higher BMD and BMC.
In this investigation the left hand grip MIVC treatment by time interaction for the
N-group showed an increase in isometric strength between the 6M and 9M time points,
whereas PL showed no significant change over time. O f interest is that this increase was
only observed with the left hand and not the right. This may have been reflective o f a
non-dominant side strength increase as a result o f anabolic steroid treatment as well as
the N group beginning at baseline with a lower grip strength than the PL group and
increasing past PL values at 9M. These data support the hypothesis due to
improvement in strength.
Isokinetic muscle strength data demonstrated increases in elbow flexors and
extensors torque over time with nandrolone treatment. Bilateral elbow flexors extensors
increased in torque production over time with both speeds (180 and 60 dps). Post hoc
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analysis did clearly demonstrate a significant response over time for torque production of
N versus the PL group.
Upper extremity total work also increased between pre- and post study for N
with respect to the right elbow flexors at both speeds and left elbow flexors at 60 dps.
There was also an observed trend for significance for treatment by time interaction for
the left elbow flexors and right elbow extensors at 180 dps at 60 dps with 9M being
greater than baseline (p = 0.059 and 0.07, respectively).
The right knee extensors also demonstrated an increase torque over time, using
180 dps, with the greatest torque for the N group observed at 6M. Why the torque
production declined after 6M is not clear, although it is possible the drug treatment
effects were maximized by 6M and declined without concurrent exercise training. At 60
dps, for all strength related variables only the PL group were observed to decline in
torque over time with baseline having the largest value and the N group was noted to
have no significant differences. The right knee flexors, alone, were observed to decline
in torque significantly for the PL with no effects on N. To the contrary bilateral knee
extensors demonstrated increased work over time only at 60 dps with no changes seen
for the knee flexors.
Overall, nandrolone treatment was associated with small but consistent increases
in muscle torque production, which supported the hypothesis o f expectation o f increased
torque production with nandrolone treatment, whereas PL torque remained
approximately the same or decreased over time. Whether the nandrolone-treated group
increases in LBM resulted in hypertrophy o f muscle tissue, as well as increases in
connective tissue in these subjects is unknown. Resistance exercise characteristically has
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been associated with increased gains in strength, particularly when combined with
anabolic steroid treatment.(25) Although resistance exercise is associated with increases
in LBM for the specific areas trained, change in % BF is not seen with anaerobic
exercise. Subsequent studies could include resistance exercise in combination with
calorie restriction and anabolic steroid treatment to facilitate increases in LBM and
torque production. Thus, new RNA and resulting protein synthesis would effect
increases in LBM and torque production. These factors could then interact with the
skeletal system to facilitate bone formation during remodeling.
Possibly, the lack o f consistency in torque production (particularly in the lower
extremities) resulted in the large standard deviation for the means for isokinetic testing
and was responsible for lack o f consistent increases in torque in all extremities tested.
Many o f the subjects had no conception o f what a maximal effort meant because they
were generally very sedentary and most had never been involved in a training program or
fitness testing.
Regardless o f the lack of effect on bone formation, improvements in torque
production occurred from treatment with nandrolone. These changes, alone could be
beneficial to many in the elderly population.

The long-term result o f no treatment

effects on bone density may have been related to the following: variation in torque
production between subjects, the major time by treatment effects appearing only in the
upper extremities and no chronic training o f the muscles via exercise. In addition, there
was no preservation o f bone mass in the forearms even though elbow flexors-elbow
extensors torque did improve over time in the N treated group. In particular since
subjects were not participating in exercise training, effects from the increase in LBM
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were minimized. This was clearly evident in terms o f the positive changes observed in
torque production o f the upper extremities without changes in forearm BMD. Small
differences in BMD over time presumably could have been detected by the DEXA if they
existed. Short-term precision for DEXA o f the spine has been observed to be 1.08%,
with long-term precision as low as 1.01%.(112)
Nandrolone treatment produced a non-significant increase in the thigh muscle
volume, whereas the PL subjects lost CSA over time. The occurrence o f a strong trend
(F = 4.48, p = 0.0514) for group effects was observed. Unfortunately, data for one o f
the N subjects at 9M was lost by the diagnostic facility where the CAT scans were
completed and analyzed. This left only n = 7 to be statistically analyzed for 9M and this
particular subject had shown a clear increase in CSA over time up to 6M. Perhaps if the
data for this subject had been included, statistically significant differences could have
been documented. Due to the lack o f documentation of statistically significant
differences between groups, the hypothesis was not supported with respect to these data.
If exercise training had been permitted possibly there would have been a further
increase in muscle volume, as well as peak torque production due to hypertrophy o f the
muscle tissue. In particular, resistance exercise training using a high strain rate and a low
number o f repetitions would have potentially yielded positive results in terms o f both
muscle and bone mass. Naturally, aerobic exercise would also be a necessary part o f the
program to facilitate weight loss, since resistance exercise is not associated with those
benefits.
With respect to the endocrine markers, 25 (OH) D3 was the only one to
demonstrate a change from baseline values. This decrease from baseline can be readily

52
attributed to the seasonal variation which normally occurs in vitamin D as less is
produced in the skin during the winter months. Subjects were initially screened and
entered the 9 month study during the summer and were followed through the fall, winter
and completed all study requirements in the spring.
It was anticipated that preservation o f bone calcium and phosphorus associated
with nandrolone treatment would occur resulting in a decline in these minerals lost in the
24-hour urine samples. Specifically what was seen was a significant decline in
phosphorus:creatinine ratio at 9M versus all other time points. Although a main effect
for time for both groups was demonstrated for the calcium:creatinine ratio, no significant
differences were noted with post hoc analysis. Contrary to the findings in this
investigation with non-osteoporotics, Need demonstrated a decrease in calcium loss in
the urine with nandrolone treatment o f osteoporotics.(93) It is important to remember that
urinary electrolyte losses can be reflective o f dietary intake as well as accounting for
bone resorption. This relationship was demonstrated with the 3M phosphorus data for
N. Additionally, there were three trends o f interest related to diet intake and urinary loss
o f minerals. The PL group was observed to show a moderate correlational trend for
dietary intake o f calcium and sodium with calciuria at baseline (r = 0.56, p = 0.054 and r
= 0.53, p = 0.064 for calcium intake and sodium intake to calcium urine loss,
respectively). Also N demonstrated a modest correlational trend related to calcium
intake and urinary loss at 1M (r = 0.46, p = 0.063) In this specific case, calcium loss in
the urine did not increase. This is substantiated by the lack o f change in osteocalcin
(OC) and alkaline phosphatase (Aik phos).
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Overall, because there were no effects o f nandrolone treatment on biochemical
and endocrine markers o f bone turnover these data did not support the hypothesis. The
small changes in % BF, LBM and muscular torque did not have any effects on bone
status, nor the bone specific markers which represent the dynamic process o f bone
resorption and formation. These results conflict with Johansen’s group which
documented both increases in LBM and BMD in osteoporotic subjects with nandrolone
treatment,(64) although the current investigation evaluated subjects with normal BMD,
presumably due to obesity.
In conclusion, the results from this study do not support the hypothesis since the
nandrolone treated group did not demonstrate bone preservation compared to PL in the
lumbar spine, bilateral forearms (total radius and ulna) and ultra-distal regions o f bilateral
forearms. Previously, nandrolone has been observed to have positive effects on bone
formation in both trabecular and cortical bone o f osteoporotic subjects. In this
investigation, these effects were not documented. A possible reason for lack o f change
could be too low a dose o f the nandrolone (normally administered at 50 mg every 3-4
weeks) and insufficient treatment time since 6-9 months was the earliest time when
changes would be observed.
Another issue which may have affected study outcome is that if this study had
used exercise training within the investigation differences in BMD and BMC when
combined with anabolic steroid therapy, may have been demonstrated. Anabolic
treatment combined with minimal weight loss did not have an effect on BMD
preservation. With exercise, the chronic and repetitive stress to the increased lean mass
could have resulted in greater hypertrophy and possible hyperplasia o f the muscle tissue
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as well as increased recruitment o f fibers. These factors would interplay effecting a
greater peak torque production, thus creating a larger load on the skeletal system. These
greater contractile forces during exercise may have acted on osteoclastic activity to
promote bone remodeling and osteoblastic processes to increase bone formation, since
Lanyon suggests that it is the strain-related stimulation for which the bone cells are not
accustomed that define the character o f the remodeling stimulus o f bone.(125' 127) It is
evident that anabolic steroid treatment, without exercise, did not mediate this activity
through biomechanical means visavis the different pattern o f change in LBM over the
study for the nandrolone-treated subjects. It is then reasonable to expect exercise
training could have potentiated this effect. Aurbach believes that physical activity may
be a critical factor in determining bone mass for the postmenopausal female:
Thus integral physical load (a function o f physical activity, muscle strength
and weight) may be a determinant of peak bone mass and may thereby help
to determine the population at risk for osteoporosis. If this concept is
correct, prophylactic exercise programs (initiated well before menopause)
should reduce the incidence o f fractures.(1)
Additionally, the use o f exercise as an integral part o f a weight loss program
cannot be over emphasized. Although exercise was strictly controlled due to possible
confounding effects, presumably subjects would have lost a greater amount o f % BF if
aerobic exercise had been combined with diet and nandrolone treatment.
Let it also be clear that bone homeostasis is not proposed to be rigidly controlled
only by biomechanical factors. Hormonal interaction to achieve calcium balance is
critical to bone status and its involvement in this process should not be minimized. In
terms o f biochemical and endocrine markers assessed in this investigation, there were no
obvious changes in the PTH-Vitamin D axis as a result o f treatment. This was also
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reflected in the non-significant changes in Aik Phos, osteocalcin and the urine calcium
and phosphorusxreatinine ratios throughout the investigation.
Although diet records did show evidence o f correlation between intake o f these
minerals to urinary output this relationship was not statistically significant for most
collection periods. There was a wide variation in calcium intake of subjects during
collection periods despite specific written instructions to consume 800 mg./day. The PL
group consumed a daily range o f 184-2006 mg. o f calcium while N intake was in the
range o f 333 to 1666 mg. over the various collection periods.
Clearly, there were several problems with controlling calcium intake during urine
collection. First, subjects demonstrated through their food records that they had no
concept o f calcium sources in whole foods since many did not even meet premenopausal
RDA requirements for daily calcium consumption. Second, since food records were
poorly kept, it is possible many foods that were eaten by subjects were not documented
and calcium, sodium or phosphorus intake may have been higher or even lower. Third,
even though there was an attempt to control intake for consistency and analysis o f
records for calcium, phosphorus and sodium, there was no evidence o f bioavailability o f
calcium in the gut and whether anabolic steroid treatment had any effects on gut
absorption o f calcium. If calcium intake was indeed well below RDA standards then this
may have contributed to bone loss, rather than preservation, with nandrolone treatment.
This problem has previously been observed in ovariectomized canines treated with
nandrolone decanoate yet ingesting calcium deficit diets.(128)
Utilization o f random urine samples rather than 24-hour collection, which is
tedious for free-living subjects, is one alternative to obtaining these important data.
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Significant correlations have been demonstrated between these two methods recently (r
= 0.967, p < 0.0001).<129) Future studies would also do well to assess gut absorption o f
calcium using stable strontium (88Sr) uptake since mechanisms o f vitamin D3 action at
the level o f the gut with anabolic steroid treatment have never been clarified.
Results from this study do not indicate that nandrolone decanoate, at the dose
used in this investigation, would serve as a suitable substitute for ERT when estrogen is
not the appropriate course o f treatment due to prior personal and family medical history.
However, further studies are suggested with this form o f drug therapy, if a larger dose
can be determined to have a greater benefit:risk ratio, for postmenopausal subjects who
may be placed at risk for increased bone resorption due to weight loss. Since it has been
shown that osteoblast-like cells have demonstrated in cell cultures to have androgen
receptors,<92) then continued investigation into this area is highly suggested. It would be
potentially beneficial for further investigations to combine drug treatment and exercise
training, as well as providing measures to gain better compliance with hypocaloric diet
regimen. Larger body weight changes are needed to better test this hypothesis, since
minimization o f weight loss did not sufficiently stress bone status in these women.
Failure o f the subjects to reach their target weight is not a new problem in
treating and studying obesity. Rather, it further emphasizes the need to approach weight
loss in a realistic manner: calorie reduction, behavior modification and exercise to
achieve goals o f weight loss. Future studies in the area o f postmenopausal women
undergoing weight loss should remain a very important focus, since these women are at
greater risk for loss o f BMD. Continued research in the area o f pharmacological
approaches to maintenance o f BMD is critical for the postmenopausal female.
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APPENDIX A: INFORMED CONSENT
The Effects of Nandrolone Decanoate, Aldactone
or Placebo on Muscular Strength,
Biochemical Markers of Bone Formation
and Bone Mineral Acquisition
I , ___________________________________ , voluntarily consent to participate in
the following investigation which is designed to determine the effects o f nandrolone
decanoate, aldactone or placebo treatment on improvement in lean body (muscle) mass,
prevention o f bone mass loss and increased bone density. I understand this is an ancillary
study to “Synthetic Hormones and Fat Distribution in Obesity” which is assessing
increased lean mass and fat loss with nandrolone or aldactone treatment.
In deciding to participate in this 9-month study, I understand that I will be
required to undergo muscle strength testing in my arms and legs at baseline (before drug
treatment) and after 3, 6, and 9 months o f drug or placebo treatment. This will consist
o f flexing and extending my arms and legs (individually) against a fixed resistance
throughout the exercise. I understand I will also have grip strength o f both hands
measured by squeezing a device maximally.
I understand I will be required to save a 24-hour urine sample at baseline, 1, 3, 6,
and 9 month intervals during the study. The purpose o f this is to measure markers in the
urine for bone formation. I understand I will be required to eat a set amount o f calcium
in my diet 24 hours prior to urine collection and during the 24 hours I collect urine. I
understand I will receive specific instructions on calcium intake and urine collection.
I understand I also will be required to have a blood sample analyzed every 3
months to determine bone formation. I understand this will not require an additional
venipuncture, rather additional blood (about 1 tsp. extra) will be drawn at the same time
a sample is drawn for Dr. Lovejoy’s main Synthetic Hormone study.
I understand I will be required to undergo bone density measurements o f both
forearms and the spine with use o f the DEXA three times during the study (baseline and
at 6 and 9 months in the study). I understand the radiation exposure from the DEXA is
40mRem which is not whole body exposure, rather specific only to the regions o f
interest (the spine and forearm). I understand that the radiation exposure from the preand post-study scans amounts to only 1/3 o f the natural background exposure for 1 year.
I understand Pennington Biomedical Research Center is paying for all testing and
personnel and I am not responsible for any payment. I also understand that in the event

physical injury resulting from research procedures, I would be personally and financially
responsible to seek medical treatment. I understand that Pennington Biomedical
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Research Center is a research facility only and would not be a source for medical
treatment.
I understand I am free to withdraw my consent to participate in this study at any
time. I also understand if I am not compliant with all study procedures, the Principal
Investigator can terminate my participation in the study.
I understand that through my participation in this study I will be contributing to
the body o f knowledge o f biomedical science. I have been informed that the results o f
this study may be published, but my privacy will be protected and my name will not be
published. I also understand that results from this study will be shared with me once the
scientific and statistical analysis is complete.
My signature on this sheet indicates that I have completely read this form and
consent to participate. I will have an opportunity to ask questions prior to the start o f
the study or at any time during the study by contacting the principal investigator, Ellen
Brooks, R.N., at 765-2560, a co-investigator, Donna Ryan, M.D. at 765-2514 or the
Clinical Trials Staff at 765-2672.

Volunteer’s Signature

Date

Social Security #__________________________________

Witness

Date

Ellen R. Brooks, R.N., M.N., Principal Investigator
Chief, Clinical Research Unit
Coordinator, Clinical Trials

Jennifer Lovejoy, Ph.D., Co-Investigator

Donna H. Ryan, M.D., Co-Investigator
Associate Executive Director for Science

APPENDIX B: TABLES

Table 3. G roup M eans for Baseline Dependent Variables
M ean + SD
V ariable
Placebo
N androlone
Body Mass (kg)
Body Mass Index
Lean Body Mass (kg)
Fat Mass (kg)
% Body Fat
Waist:Hip Ratio
Arm Circumference (cm)
CSA Thigh (cm2)
BMD L2-L4 (gm/cm2)
Left Forearm Total BMD
(gm/cm2)
Right Forearm Total BMD
(gm/cm2)

86.4 ± 7.3
33.4 + 2.9
41.2 ± 4 .9
43.3 ± 5 .6
49.3 ± 4 .6
0.86 ± 0.0 6
37.4 ± 2 .5
71.1 ± 10.9
0.963 ± 0.132

87.1 ± 8 .6
33.9 ± 4 .3
40.1 ± 2 .5
43.7 ± 6 .5
50.7 ± 2 .9
0.83 ± 0.0 5
36.4 ± 3.1
71.8 ± 6 .8
0.940 ± 0.127

0.562 + 0.620

0.547 + 0.530

0.567 ± 0.630

0.544 ± 0.520

Table 4. Lean Body Mass (kg) over 9 M onths in Subjects Treated with
Placebo (N=10) or Nandrolone (N=8)
G roun
Time
M ean + Std. Dev.
PL
41.2 ± 4.9
B/L
N
B/L
40.1 ± 2.5
PL
40.5 ± 4 .5
3M
N
41.0 ± 2.8
3M
PL
40.0 ± 4 .5
6M
43.1 ± 3.3
N
6M
PL
39.9 ± 4 .4
9M
43.0 + 3.8
N
9M
Time * treatment interaction ANOVA p = 0.0001
Post hoc analysis: a = 0.025
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Table 5. Percent Body F at over 9 M onths in Subjects Treated
with Placebo o r Nandrolone
M ean + Std. Dev.
Time
G roun
49.3 ± 4 .7
BL
PL
50.7 + 2.9
BL
N
46.9 + 5.0
3M
PL
47.8 ± 4 .3
3M
N
47.1 ± 6 .0
6M
PL
45.7 ± 4 .4
6M
N
47.5 + 5.8
9M
PL
45.9 ± 5.1
9M
N
Time * treatment interaction ANOVA p = 0.013
Post hoc analysis: a = 0.025

Table 6. L u m b ar Bone M ineral Density (gm/cm2! over 9 M onths
G roun
Time
M ean + Std. Dev.
PL
BL
0.963 ± 0.132
BL
0.940 ± 0.127
N
6M
0.974 ±0.138
PL
6M
0.910 ± 0.100
N
PL
9M
0.963 ± 0.137
9M
N
0.930 + 0.125
Time * treatment interaction ANOVA p = 0.020
Post hoc analysis: a = 0.025
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Table 7. Left M aximal Isom etric Voluntary C ontraction
(Newtons!
Time
M ean + Std. Dev.
GrouD
BL
311.2 + 37.2
PL
BL
276.2 + 42.6
N
3M
309.2 + 37.5
PL
3M
300.7 + 61.9
N
6M
300.6 + 36.5
PL
6M
286.0 + 55.6
N
9M
297.1 + 48.9
PL
9M
313.1 + 52.7
N
Time * treatment interaction ANOVA p = 0.03
Post hoc analysis: a = 0.025

Table 8. R ight Elbow Flexors Torque at 180 Degrees p er Second
9 M onths (Newton-M etersl
Peak T oraue
Time
M ean Toraue
Peak Toraue/B odv M ass
G roun
19.4 + 2.5
0.226 + 0.037
BL
17.1+2.1
PL
15.4
+
5.6
BL
0.179
+ 0.066
N
13.3+ 4.7
18.5+ 4.5
0.226 + 0.056
PL
3M
16.7 + 4.8
18.7 + 3.9
3M
0.223 + 0.049
N
16.6 + 4.0
18.3+ 4.6
6M
0.227 + 0.054
PL
17.0 + 4.7
20.8 + 3.3
6M
19.1+3.3
0.250 + 0.057
N
17.9 + 5.0
9M
16.2 + 5.1
0.222 + 0.058
PL
21.0 + 5.6
9M
19.4 + 5.8
0.250 + 0.078
N

Variables are expressed as means ± std. dev.
Peak torque time * treatment interaction ANOVA p = 0.013
Mean torque time * treatment interaction ANOVA p = 0.016
Peak torque/body mass time * treatment interaction ANOVA p = 0.034
Post Hoc Analysis: a = 0.025
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Table 9. Left Elbow Flexors Torque at 60 Degrees per Second over 9
___________________
Months (Newton-Metersl______________
Peak Torauc/B M
Time
Peak T oraue M ean T oraue
G roun
22.5 ± 6 .2
20.0 ± 4 .6
0.260 ±0.067
BL
PL
20.9 ± 3 .4
18.8 ± 3 .2
0.239 ± 0.034
N
BL
23.6 ± 5 .2
21.6 ± 4.3
0.292 ± 0.067
PL
3M
24.3 ± 4 .4
22.6 ± 4 .2
0.292 ± 0.057
3M
N
23.5 ± 4 .6
21.6 ± 3.6
0.291 ±0.053
PL
6M
26.2 ± 6.3
24.0 ± 5 .6
6M
0.310 ±0.075
N
23.0 ± 5 .6
21.0 ± 4.2
PL
9M
0.282 ± 0.065
27.5 ± 6 .2
25.0 ± 6 .4
0.327 ± 0.086
9M
N
Variables are expressed as mean ± std. dev.
Peak torque time * treatment interaction ANOVA p = 0.004
Mean torque time * treatment interaction ANOVA p = 0.02
Peak torque/body mass time * treatment interaction ANOVA p = 0.03
Post Hoc Analysis: a = 0.025

Table 10. Left Elbow Flexors Torque at 180 Degrees p er Second
_____________________(Newton-M etersl_________________ _
M ean T oraue
Time Peak Toraue
Peak T oraue/B odv Mass
G roun
15.9 ± 3.6
19.6 ± 5 .2
PL
BL
0.227 ± 0.063
14.9 ± 2 .4
BL
17.4 ± 1.9
0.201 ± 0.027
N
17.3 ± 5 .0
PL
3M
19.6 ± 4.7
0.241 ±0.064
17.2 ± 3 .8
3M
19.5 ± 3 .9
0.235 ± 0.047
N
17.7 ± 3.9
PL
6M
19.5 ±4.3
0.241 ± 0.057
17.4 ± 5 .6
6M
20.5 ± 5.8
0.241 ± 0.059
N
18.5
±
3
.2
16.2
±
3.8
PL
9M
0.229 ± 0.043
20.1 +7.5
9M
23.4 ± 8 .6
0.278 + 0.109
N
Variables are expressed as mean ± std. dev.
Peak torque treatment * time interaction ANOVA p = 0.013
Mean torque treatment * time interaction ANOVA p= 0.02
Peak torque/body mass treatment * time interaction ANOVA p = 0.03
Post hoc analysis: a - 0.0225
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Table 11. Left Elbow Flexors Torque at 60 Degrees per Second
________________________ (Newton-Meters)________________
Group
Time
Peak Toraue
Mean Toraue Peak Torque/Bodv Mass
0.260 ± 0.067
20.0 ± 4 .6
BL
22.5 ± 6 .2
PL
0.239 ± 0.034
BL
20.9 ± 3 .4
18.8 ± 3 .2
N
0.292 + 0.067
3M
24.0 ± 5 .2
PL
21.6 ± 4.3
0.292 ± 0.060
24.3
±
4.4
22.6
±
4
.2
N
3M
0.291 ±0.053
6M
23.5 ± 4 .6
21.6 ± 3.6
PL
24.0
±
5
.6
0.310 ± 0.080
6M
26.2
±
6.3
N
23.0 ± 5 .7
21.0 ± 4.2
0.282 ±0.065
PL
9M
0.330 ± 0.090
9M
27.5 ± 6 .2
25.0 ± 6 .4
N
Variables are expressed as mean ± std. dev.
peak torque treatment * time interation ANOVA p = 0.004
mean torque treatment * time interaction ANOVA p = 0.02
peak torque/body mass treatment * time interaction ANOVA p = 0.03
Post hoc analysis: a = 0.025

Table 12. Torque for Right and Left Elbow Extensors at 180 Degrees
____________ per Second over 9 Months (Newton-Metersl ___________________
Right
Left
Group Time Peak Toraue Peak Toraue/BM Peak Toraue Peak Toraue/BM
PL
BL
16.1 ± 2 .9
17.8 ± 3.5
0.2 ± 0.04
0.187 ± 0.400
BL
N
0.2 ± 0.05
14.1 ± 4.1
0.160 ± 0.042
14.6 ±4.3
PL
3M
16.0 ± 4 .3
0.200 ± 0.060
17.1 ± 3.4
0.2 ±0.05
N
3M
16.4 ± 4 .2
0.195 ± 0.050
16.5 ± 2 .7
0.2 ± 0.04
PL
6M
17.7 ± 3.2
16.2
±
3
.4
0.2 ± 0.05
0.201 ±0.045
6M
N
18.6 ± 3.5
17.1 ± 4 .2
0.204 ± 0.050
0.2 ±0.05
PL
9M
15.9 ± 3 .1
15.9 ± 3.2
0.2 ± 0.04
0.197 ± 0.036
N
9M
18.0 ± 5.2
0.220 + 0.700
19.0 + 5.6
0.2 + 0.08
Variables are expressed as mean ± std. dev.
Peak torque time * treatment interaction ANOVA p = 0.005
Peak torque/body mass time * treatment interaction ANOVA p = 0.014
Peak torque time * treatment interaction ANOVA p = 0.032
Peak torque/body mass time * treatment interaction ANOVA p = 0.05
(Post hoc analysis: a = 0.025)
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Table 13. Right Knee Extensors Torque at 180 Degrees per Second
_____________
(N ewton-Meters)____________________
Group
Time
Peak Torque
Mean Torque Peak Torque/Body Mass
70.4 ± 21.6
0.885 ± 0.255
76.5 ±22.3
PL
BL
64.1
±
10.8
0.777 ± 0.093
BL
67.5 ± 9.02
N
0.845 ± 0.232
68.7 ± 16.7
PL
3M
65.5 ± 17.4
0.795 ± 0.156
66.4
±
12.1
3M
N
61.5 ± 14.6
0.954 ± 0.260
PL
6M
76.7 ± 18.0
69.5 ± 18.2
1.054 ± 0.238
88.0 ± 15.6
80.2 ± 15.8
6M
N
0.850 ± 0.252
69.0 ± 19.1
63.8 ± 16.2
PL
9M
64.2 ± 16.6
0.853 ± 0 .1 8 4
N
9M
72.0 ± 14.7
Variables are expressed as mean ± std. dev.
peak torque treatment * time interaction ANOVA p = 0.02
mean torque treatment * time interaction ANOVA p =0.008
peak torque/body mass treatment * time interaction ANOVA p = 0.009
Post hoc analysis: a = 0.025

Table 14. Right Knee Extensors Torque at 60 Degrees per Second
__________
(Newton-Meters!___________________________________
Group Time
Peak Torque
Mean Torque
Peak Torque/Bodv Mass
BL
1.3 ± 0 .3
PL
115.5 ±24.1
110.2 ± 25 .0
BL
110.2 ± 19.0
104.0 ± 21.0
1.3 ± 0 .2
N
1.3 ± 0 .4
PL
3M
107.0 ±25.5
102.0 ± 24 .2
1.3 ± 0 .3
3M
106.0 ± 26.0
100.0 ± 27 .0
N
6M
1.3 ± 0 .3
PL
106.0 ± 25,0
98.0 ± 26.0
6M
116.4 ± 23.0
109.2 ±22.3
1.4 ± 0 .3
N
9M
PL
99.4 ±23.1
93.0 ±22.3
1.2 ± 0 .3
9M
1.4+ 0.3
N
115.0 + 22.1
108.3 +23.0
Variables are expressed as mean ± std. dev.
Peak torque treatment * time interaction ANOVA p = 0.0003
Mean torque treatment * time interaction ANOVA p = 0.0002
Peak torque/body mass treatment * time interaction ANOVA p = 0.004
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Table 15. Right Knee Flexors Mean Torque at 60 Degrees per Second
_________
(Newton-Metersl_________________ _____
M ean + Std. Dev.
Time
G roun
70.2 ± 12.8
PL
BL
69.1 ± 13.9
BL
N
72.4 ± 12.8
PL
3M
66.4 ± 12.7
N
3M
72.4 ± 14.2
PL
6M
76.1 ± 14.0
N
6M
64.7 ± 10.2
9M
PL
71.0 ± 12.0
9M
N
Mean torque treatment * time interaction ANOVA p = 0.03

Table 16. R ight Elbow Flexors Total W ork a t 60 Degrees p er Second
____________________
fNewton-Meters)________ _____________
Time
M ean + Std. Dev.
GrouD
190.6 + 22.7
PL
BL
174.2+51.9
N
BL
PL
9M
186.0 + 32.0
N
9M
238.5 + 65.6
Total work treatment * time interaction ANOVA p = 0.0004
Post hoc analysis: a = 0.025
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Table 17. Left Elbow Extensors Total W ork a t 180 Degrees p er Second
(Newton-Meters)
M ean + Std. Dev.
Time
GrouD
47.5 + 18.0
BL
PL
BL
43.0+ 11.1
N
4 7 .7 + 1 2 .0
9M
PL
9M
57.8 ± 21 .4
N
Total work trend for treatment * time interaction ANOVA p = 0.06

Table 18. R ight Elbow Extensors Total W ork at 60 Degrees per Second
______
(Newton-M etersl________________________
Time
M ean + Std. Dev.
GrouD
BL
PL
194.4 + 40.0
BL
N
187.4 + 49.3
9M
PL
192.2 + 35.3
9M
N
241.0 ± 9 4 .0
Total work treatment * time interaction ANOVA p = 0.014
Post hoc analysis: a ==0.025

LBM (kg)
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Figure 1. Lean body mass treatment by time interaction (p=0.0001) (Mean ± SD).

79

80

60 -g
55 ■;
50 {

%BF

45
40 z,

----

35 -j

o—

3 0 •:

PL
N

25 -j

20 ■!
15 -

1 ------------------------1------------------------ 1------------------------ r *

BL

3M

6M

9M

Month

Figure 2. % Body fat (BF) treatment by time interaction (p=0.013) (Mean ± SD)

81

1.15-

s

1.10 -

6

1.05-

§

1.00-

3i

0 .9 5 -

(N
_J

0 .9 0 -

CQ 0 .8 5 0 .8 0 0 .7 5 -

Month

Figure 3. Lumbar bone minteral density (BMD) treatment by time interaction (p=0.02)
(Mean ± SD).
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Figure 4. Left maximal isometric voluntary contraction treatment by time interaction
(p=0.03) (Mean ± SD).
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Figure 5. Right elbow flexors peak torque (180 degrees/second) treatment by time
interaction (p=().0()()3) (Mean + SD).
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Figure 6. Isokinetic mean torque for right elbow flexors at 180 degrees/second treatment
by time interaction (p=0.0009) (Mean ± SD).
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Figure 7. Isokinetic right elbow flexors peak torque/body mass treatment by time
interaction 180 degrees/second (p=0.002) (Mean ± SD).
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Figure 8. Left elbow flexors at 180 degrees/second peak torque treatment by time
interaction (p=0.013) (Mean ± SD).
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Figure 9. Left elbow flexors mean torque at 180 degrees/second treatment by time
interaction (p=0.02) (Mean ± SD).
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Figure 10. Peak torque/body mass left elbow flexors treatment by time interaction
(p=0.034) (Mean ± SD).
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Figure 11. Mean torque for right elbow flexors treatment by time interaction at 60
degrees/second (p=0.042) (Mean ± SD).
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Figure 12. Peak torque at 60 degrees/second treatment by time interaction (p=0.004) for
left elbow flexors (Mean ± SD).
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Figure 13. Mean torque for left elbow flexors at 60 degrees/second treatment by time
interaction (p=0.02) (Mean ± SD).
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Figure 14. Peak torque/body mass at 60 degrees/second treatment by time interaction
(p=0.03) for left elbow flexors (Mean ± SD).
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Figure 15. Peak torque for right elbow extensors treatment by time interaction (p=0.005)
at 180 degrees/second (Mean ± SD).
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Figure 16. Peak torque/body mass at 180 degrees/second for right elbow extensors
treatment by time interaction (p=0.014) (Mean ± SD).
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Figure 17. Peak torque at 180 degrees/second treatment by time interaction (p=0.03) for
left elbow extensors (Mean ± SD).

(180 dps) Left Elbow Extensors
(Nm)

96

0.30
0.25

0.20

*
o

0.10

PkTq/BM

0 .0 5 -

0.00

- i

BL

i

i----------------------------- 1—

3M

6M

9M

Month

Figure 18. Peak torque/body mass for left elbow extensors at 180 degrees/second
treatment by time interaction (p=0.Q5) (Mean ± SD).
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Figure 19. Right knee extensors peak torque/body mass at 180 degrees/second treatment
by time interaction (p=0.009) (Mean ± SD).
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Figure 20. Mean torque for right knee extensors at 180 degrees/second treatment by time
interaction (p=0.008) (Mean ± SD).
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Figure 21. Peak torque/body mass for right knee extensors at 180 degrees/second
treatment by time interaction (p=G.009) (Mean ± SD).
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Figure 22. Peak torque for right knee extensors at 60 degrees/second treatment by time
interaction (p=0.0003) (Mean ± SD).
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Figure 23. Mean torque at 60 degrees/second treatment by time interaction (p=0.0002)
(Mean ± SD).
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Figure 24. Peak torque/body mass for right knee extensors at 60 degrees/second
treatment by time interaction (p=Q.004) (Mean ± SD).
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Figure 25. Mean torque for right knee flexors at 60 degrees/second treatment by time
interaction (p=0.03) (Mean ± SD).
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Figure 26. Total work right elbow flexors at 180 degrees/second treatment by time
interaction (p=0.02) (Mean ± SD).
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Figure 27. Total work at 60 degrees/second right elbow flexors treatment by time
interaction (p=0.0004) (Mean ± SD).
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Figure 28. Total work of left elbow flextors at 60 degrees/second treatment by time
interaction (p=0.0002) (Mean + SD).
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Figure 29. Total work at 60 degrees/second right elbow extensors treatment by time
interaction (p=0.014) (Mean ± SD).
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Figure 30. Cross-sectional area of the thigh trend in treatment effects (p=0.()51) (Mean ±
SD).
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